Combination therapy for treatment of mastocytosis

JP2024063227A5Active Publication Date: 2024-12-03DECIPHERA PHARMACEUTICALS LLC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024035451
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-01-31
Filing Date
2024-03-08
Publication Date
2024-12-03
Estimated Expiration
2039-01-31

AI Technical Summary

Technical Problem

Current treatments for mastocytosis, particularly those involving c-KIT inhibitors, are ineffective against the c-KIT D816V mutation and often have significant side effects, leading to resistant and aggressive forms of the disease.

Method used

A combination therapy using a c-KIT inhibitor, such as Compound A or B, in conjunction with MEK, ERK, or RAF inhibitors like trametinib, binimetinib, or LY3009120, is administered to induce apoptosis and inhibit mast cell proliferation, effectively targeting both primary and secondary c-KIT mutations.

Benefits of technology

The combination therapy synergistically induces mast cell apoptosis and inhibits proliferation, offering a cytolethal effect rather than merely cytostatic, effectively reducing mast cell accumulation and symptoms in tissues and organs, including tumors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024063227000001
    Figure 2024063227000001
  • Figure 2024063227000002
    Figure 2024063227000002
  • Figure 2024063227000003
    Figure 2024063227000003
Patent Text Reader

Abstract

To provide a method for the treatment of mastocytosis.SOLUTION: The present disclosure relates to the use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea or 1-(5-(7-amino-1-ethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-4-bromo-2-fluorophenyl)-3-phenylurea, or a pharmaceutically acceptable salt thereof, in combination with a MAPKAP pathway inhibitor such as a RAS, RAF, MEK or ERK inhibitor.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Background technology]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Patent Application No. 62 / 624,453, filed January 31, 2018, which is incorporated by reference in its entirety.

[0002] c-KIT (also known as KIT, CD117, and stem cell factor receptor) is a 145 kDa transmembrane tyrosine kinase protein that acts as a type III receptor. The c-KIT proto-oncogene, located on chromosome 4q11-21, encodes the c-KIT receptor, whose ligand is stem cell factor (SCF, hematopoietic stem cell factor, kit ligand, mast cell growth factor). The receptor has tyrosine protein kinase activity, and binding of the ligand SCF leads to the autophosphorylation of c-KIT and its association with substrates such as phosphatidylinositol 3-kinase (PI3K). Tyrosine phosphorylation by protein tyrosine kinases is particularly important in cell signaling and can mediate signals for key intracellular processes such as proliferation, survival, differentiation, apoptosis, adhesion, invasion, and migration.

[0003] The receptor tyrosine kinase c-KIT gene is important for mast cell proliferation, survival, differentiation and homeostasis. Activating mutations or overexpression of the c-KIT gene increase the ability of the c-KIT receptor to initiate intracellular pathways that result in abnormal mast cell proliferation.

[0004] Mastocytosis is a rare disorder characterized by abnormal accumulation of mast cells (MCs) in the skin, bone marrow, and internal organs (e.g., liver, spleen, gastrointestinal tract, and lymph nodes). Cases beginning in adulthood tend to be chronic and involve bone marrow in addition to skin, whereas in childhood, symptoms are often characterized by skin symptoms without visceral involvement and can often resolve during adolescence. In most adult patients, mastocytosis tends to be persistent, and in a minority of patients, it may progress to more advanced categories. Mastocytosis can be classified into specific types depending on the patient's symptoms and overall condition. Types of mastocytosis include cutaneous mastocytosis (e.g., maculopapular cutaneous mastocytosis, mastocytoma, and diffuse cutaneous mastocytosis) and systemic mastocytosis (e.g., indolent systemic mastocytosis (ISM), smoldering systemic mastocytosis (SSM), systemic mastocytosis with associated clonal hematologic non-mast cell lineage disease (SM-AHN), aggressive systemic mastocytosis (ASM), mast cell leukemia (MCL), and mast cell sarcoma). In rare cases, invasive neoplastic mast cell proliferation results in end-organ damage, and patients experience a severely shortened life span and require cytoreductive therapy. The pathological accumulation of neoplastic mast cells caused by oncogenic mutations in c-KIT has been found to be the cause of systemic mastocytosis. The major activating KIT mutation is an aspartic acid to valine substitution at residue 816 (KIT D816V). Patients with systemic mastocytosis, whose mast cells frequently contain the activating D816V c-KIT mutation, may be inactive against invasive disease and may experience symptoms related to mast cell mediator release. Inactive systemic mastocytosis with recurrent anaphylaxis or vascular collapse without the presence of skin lesions is a specific subtype of inactive systemic mastocytosis, and this clonal MC activation disorder represents a significant proportion of all mast cell activation syndromes. The V560G KIT mutation is extremely rare in patients with systemic mastocytosis, and its biological and prognostic impact is unknown. Currently, most tyrosine kinase inhibitors show only modest efficacy in advanced disease states and are associated with significant side effects. Furthermore, the KIT D816V mutation is a rare clonal MC activation disorder that represents a significant proportion of all mast cell activation syndromes. The V560G KIT ... Currently, most tyrosine kinase inhibitors show only modest efficacy in advanced disease states and are associated with significant side effects. Furthermore, the KIT D816V mutation is a rare clonal MC activation disorder that represents a significant proportion of all mast cell activation syndromes. Some aggressive KIT mutations, including those listed in Table 1, are resistant to classical ATP-competitive KIT inhibitors such as imatinib, sunitinib, sorafenib, and regorafenib. An inhibitor of c-KIT D816V, midostaurin, was recently approved for the treatment of SM in 2017.

[0005] Although the c-KIT D816V mutation is the c-KIT primary mutation reported as a driver of systemic mastocytosis (SM), secondary c-KIT mutations conferring resistance to certain c-KIT inhibitors ("resistant c-KIT secondary mutations") have also been reported in mastocytosis patients, including, for example, Y269C, Y503_F504insAY, V560D, or K642E point mutations, in-frame deletions or insertions, or missense mutations in the c-KIT gene.

[0006] Activating mutations or overexpression of the c-KIT gene lead to neoplastic mast cell proliferation. Given the complex functions of c-KIT and the potential utility of c-KIT inhibitors in treating drug-resistant systemic mastocytosis, there is a need for inhibitors and therapeutic treatments with beneficial therapeutic properties. Summary of the Invention

[0007] The disclosure relates in part to the use of c-KIT inhibitors, such as 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea (Compound A), and MAPKAP pathway inhibitors, such as MEK inhibitors, such as trametinib, or ERK inhibitors, such as ulixertinib, or RAF inhibitors, such as LY3009120, to induce apoptosis of mastocytosis cells.

[0008] Provided in the present disclosure is a method of treating mastocytosis in a patient in need thereof, comprising administering to the patient an effective amount of a c-KIT inhibitor, e.g., 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea (Compound A as described herein), and an effective amount of an inhibitor of mitogen-activated protein kinase (MEK inhibitor), and / or an effective amount of an extracellular signal-regulated kinase inhibitor (ERK inhibitor).

[0009] For example, a method for treating systemic mastocytosis in a patient in need thereof includes administering to the patient an effective amount of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea or a pharma- ceutically acceptable salt thereof, and an effective amount of an inhibitor of mitogen-activated protein kinase (MEK inhibitor) or an ERK inhibitor.

[0010] Also contemplated in this disclosure is a method of treating mastocytosis in a patient in need thereof, comprising administering to the patient an effective amount of a c-KIT inhibitor and an effective amount of a RAF inhibitor. [Brief description of the drawings]

[0011] [Figure 1-1] FIG. 1A shows a graphical representation of cell proliferation following treatment with the indicated agents together with Compound A compared to vehicle control in HMC1.1 V560G (left panel) and HMC1.2 V560G / D816V (right panel) cell lines.

[0012] [Figure 1-2] FIG. 1B shows a graphical representation of cell proliferation following treatment with the indicated agents together with Compound B compared to vehicle control in HMC1.1 V560G (left panel) and HMC1.2 V560G / D816V (right panel) cell lines.

[0013] [Figure 2-1] FIG. 2A shows a graphical representation of caspase activity in the HMC1.2 V560G / D816V cell line after various indicated treatments with Compound A and trametinib.

[0014] [Figure 2-2] FIG. 2B provides a synergy matrix diagram based on the combination index method for various treatments with Compound A and trametinib in HMC1.2 V560G / D816V cell line.

[0015] [Figure 2-3] FIG. 2C provides a combination index plot for the combination of the MEK inhibitor trametinib with Compound A.

[0016] [Figure 3-1] FIG. 3A shows a graphical representation of caspase activity in the HMC1.2 V560G / D816V cell line after various indicated treatments with Compound B and trametinib.

[0017] [Figure 3-2] FIG. 3B provides a synergy matrix diagram based on the combination index method for various treatments with Compound B and trametinib in HMC1.2 V560G / D816V cell line.

[0018] [Figure 3-3] FIG. 3C provides a combination index plot for the combination of the MEK inhibitor trametinib with Compound B.

[0019] [Figure 4-1] FIG. 4A shows a graphical representation of caspase activity after various indicated treatments with Compound A and binimetinib in the HMC1.2 V560G / D816V cell line.

[0020] [Figure 4-2] FIG. 4B provides a synergy matrix diagram based on the combination index method for various treatments with Compound A and binimetinib in HMC1.2 V560G / D816V cell line.

[0021] [Figure 4-3] FIG. 4C provides a combination index plot for the combination of the MEK inhibitor binimetinib with Compound A.

[0022] [Figure 5-1] FIG. 5A shows a graphical representation of caspase activity in the HMC1.2 V560G / D816V cell line after various indicated treatments with Compound B and binimetinib.

[0023] [Figure 5-2] FIG. 5B provides a synergy matrix diagram based on the combination index method for various treatments with Compound B and binimetinib in HMC1.2 V560G / D816V cell line.

[0024] [Figure 5-3] FIG. 5C provides a combination index plot for the combination of the MEK inhibitor binimetinib with Compound B.

[0025] [Figure 6-1] FIG. 6A shows a graphical representation of caspase activity after various indicated treatments with Compound A and cobimetinib in the HMC1.2 V560G / D816V cell line.

[0026] [Figure 6-2] FIG. 6B provides a synergy matrix diagram based on the combination index method for various treatments with Compound A and cobimetinib in HMC1.2 V560G / D816V cell line.

[0027] [Figure 6-3] FIG. 6C provides a combination index plot for the combination of the MEK inhibitor cobimetinib with Compound A.

[0028] [Figure 7-1] FIG. 7A shows a graphical representation of caspase activity after various indicated treatments with Compound B and cobimetinib in the HMC1.2 V560G / D816V cell line.

[0029] [Figure 7-2] FIG. 7B provides a synergy matrix diagram based on the combination index method for various treatments with Compound B and cobimetinib in HMC1.2 V560G / D816V cell line.

[0030] [Figure 7-3] FIG. 7C provides a combination index plot for the combination of the MEK inhibitor cobimetinib with Compound B.

[0031] [Figure 8-1] FIG. 8A shows a graphical representation of caspase activity after various indicated treatments with Compound A and the ERK inhibitor ulixertinib in the HMC1.2 V560G / D816V cell line.

[0032] [Figure 8-2] FIG. 8B provides a synergy matrix diagram based on the combination index method for various treatments with Compound A and the ERK inhibitor ulixertinib in HMC1.2 V560G / D816V cell line.

[0033] [Figure 8-3] FIG. 8C provides a combination index plot for the combination of the ERK inhibitor ulixertinib with Compound A.

[0034] [Figure 9] FIG. 9A shows inhibition of colony growth from treatment with single agent Compound A, single agent trametinib, and the combination of the MEK inhibitor trametinib with Compound A in HMC1.2 V560G / D816V cells.

[0035] Figure 9B shows a graphical representation of the inhibition of colony growth from treatment with single agent Compound A, single agent trametinib, and the combination of the MEK inhibitor trametinib and Compound A in HMC1.2 V560G / D816V cells. Arrows indicate the absence of colony growth.

[0036] [Figure 10] FIG. 10A shows inhibition of colony growth from treatment with single agent Compound B, single agent trametinib, and the combination of the MEK inhibitor trametinib with Compound B in HMC1.2 V560G / D816V cells.

[0037] 10B shows a graphical representation of the inhibition of colony growth from treatment with single agent Compound B, single agent trametinib, and the combination of the MEK inhibitor trametinib with Compound B in HMC1.2 V560G / D816V cells. Arrows indicate the absence of colony growth.

[0038] [Figure 11] FIG. 11A shows inhibition of colony growth from treatment with single agent Compound A, single agent binimetinib, and the combination of the MEK inhibitor binimetinib with Compound A in HMC1.2 V560G / D816V cells.

[0039] FIG. 11B shows the results of single agent Compound A, single agent Compound B, and single agent Compound C in HMC1.2 V560G / D816V cells. 1 shows a graphical representation of the inhibition of colony growth from treatment with the MEK inhibitor binimetinib and the combination of the MEK inhibitor binimetinib with Compound A. Arrows indicate the absence of colony growth.

[0040] [Figure 12] FIG. 12A shows inhibition of colony growth from treatment with single agent Compound B, single agent binimetinib, and the combination of the MEK inhibitor binimetinib with Compound B in HMC1.2 V560G / D816V cells.

[0041] 12B shows a graphical representation of the inhibition of colony growth from treatment with single agent Compound B, single agent binimetinib, and the combination of the MEK inhibitor binimetinib with Compound B in HMC1.2 V560G / D816V cells. Arrows indicate the absence of colony growth.

[0042] [Figure 13] FIG. 13A shows inhibition of colony growth from treatment with single agent Compound A, single agent cobimetinib, and the combination of the MEK inhibitor cobinimetinib with Compound A in HMC1.2 V560G / D816V cells.

[0043] FIG. 13B shows a graphical representation of the inhibition of colony growth from treatment with single agent Compound A, single agent cobimetinib, and the combination of the MEK inhibitor cobimetinib with Compound A in HMC1.2 V560G / D816V cells.

[0044] [Figure 14] FIG. 14A shows inhibition of colony growth from treatment with single agent Compound B, single agent cobimetinib, and the combination of the MEK inhibitor cobimetinib with Compound B in HMC1.2 V560G / D816V cells.

[0045] FIG. 14B shows a graphical representation of the inhibition of colony growth from treatment with single agent Compound B, single agent cobimetinib, and the combination of the MEK inhibitor cobimetinib with Compound B in HMC1.2 V560G / D816V cells.

[0046] [Figure 15] FIG. 15A shows a graphical representation of caspase activity after various treatments with Compound A and trametinib in HMC1.2 V560G / D816V cells transfected with empty vector (EV, left panel) or N-ras G12D (right panel) at 24 hours.

[0047] FIG. 15B shows a graphical representation of caspase activity after various treatments with Compound A and trametinib in HMC1.2 V560G / D816V cells transfected with empty vector (left panel) or N-ras G12D (right panel) at 48 hours.

[0048] [Figure 16] FIG. 16A shows a graphical representation of caspase activity after various treatments with Compound A and cobimetinib in HMC1.2 V560G / D816V cells transfected with empty vector (EV, left panel) or N-ras G12D (right panel) at 24 hours.

[0049] FIG. 16B shows a graphical representation of caspase activity after various treatments with Compound A and cobimetinib in HMC1.2 V560G / D816V cells transfected with empty vector (left panel), or N-ras G12D (right panel) at 48 hours.

[0050] [Figure 17-1] FIG. 17A shows inhibition of colony growth from treatment with single agent Compound A, single agent trametinib, and the combination of the MEK inhibitor trametinib with Compound A in empty vector (EV)-transfected HMC1.2 V560G / D816V cells.

[0051] FIG. 17B shows empty vector (EV)-transfected HMC1.2 V560G / D81 1 shows a graphical representation of the inhibition of colony growth from treatment with single agent Compound A, single agent trametinib, and the combination of the MEK inhibitor trametinib with Compound A in 6V cells. Arrows indicate the absence of colony growth.

[0052] [Figure 17-2] FIG. 17C shows inhibition of colony growth from treatment with single agent Compound A, single agent trametinib, and the combination of the MEK inhibitor trametinib and Compound A in N-ras G12D-transfected HMC1.2 V560G / D816V cells.

[0053] Figure 17D shows a graphical representation of the inhibition of colony growth from treatment with single agent Compound A, single agent trametinib, and the combination of the MEK inhibitor trametinib and Compound 1 in N-ras G12D-transfected HMC1.2 V560G / D816V cells. Arrows indicate the absence of colony growth.

[0054] [Figure 18-1] FIG. 18A shows inhibition of colony growth from treatment with single agent Compound A, single agent cobimetinib, and the combination of the MEK inhibitor cobimetinib with Compound A in empty vector (EV)-transfected HMC1.2 V560G / D816V cells.

[0055] Figure 18B shows inhibition of colony growth from treatment with single agent Compound A, single agent cobimetinib, and the combination of the MEK inhibitor cobimetinib and Compound A in empty vector (EV)-transfected HMC1.2 V560G / D816V cells. Arrows indicate absence of colony growth.

[0056] [Figure 18-2] FIG. 18C shows inhibition of colony growth from treatment with single agent Compound A, single agent cobimetinib, and the combination of the MEK inhibitor cobimetinib and Compound A in N-ras G12D-transfected HMC1.2 V560G / D816V cells.

[0057] Figure 18D shows a graphical representation of the inhibition of colony growth from treatment with single agent Compound A, single agent cobimetinib, and the combination of the MEK inhibitor cobimetinib and Compound A in N-ras G12D-transfected HMC1.2V560G / D816V cells. Arrows indicate the absence of colony growth. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0058] As shown in the accompanying examples, the combination of a c-KIT inhibitor, e.g., 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea (Compound A), with a MAPKAP pathway inhibitor, e.g., the MEK inhibitor trametinib, or the ERK inhibitor ulixertinib, or the RAF inhibitor LY3009120, is unexpectedly found to synergize to induce apoptosis of mastocytosis cells. In addition, the combination therapy disclosed herein is cell lethal as opposed to merely cytostatic.

[0059] Without wishing to be bound by any particular theory, it is believed that many c-KIT inhibitors only inhibit certain mutant forms of c-KIT and do not effectively inhibit the c-KIT D816V mutation responsible for SM. The present disclosure provides a method of treating c-KIT-mediated mastocytosis by inhibiting both c-KIT and MEK using a c-KIT inhibitor in combination with a MAPKAP pathway inhibitor. In certain embodiments, the c-KIT inhibitor is referred to herein as Compound A or a pharma- ceutical acceptable salt thereof, Compound B or a pharma-ceutical acceptable salt thereof, midostaurin or a pharma-ceutical acceptable salt thereof, BLU-285 or a pharma-ceutical acceptable salt thereof, PLX9486 or a pharma-ceutical acceptable salt thereof, or crenolanib or Surprisingly, c-KIT inhibitors, e.g., Compound A and Compound B (and their pharma- ceutically acceptable salts), act synergistically with inhibitors of MEK, ERK, or RAF to inhibit proliferation of mastocytosis cells and induce apoptosis of mastocytosis cells.

[0060]

[0060] Thus, in certain embodiments, the present disclosure provides methods of inducing cytotoxic mast cell death, inducing mast cell apoptosis, inhibiting mast cell growth or proliferation, inhibiting mast cell mediator release, reducing the amount of accumulated mast cells in a tissue or organ, reducing the volume of mastocytosis-associated tumors, e.g., mast cell leukemia or mast cell sarcoma, and / or inhibiting mast cell regrowth, by contacting a mast cell, e.g., a mast cell comprising a c-KIT mutation, with a c-KIT inhibitor and a MAPKAP pathway inhibitor. In various embodiments, the mast cell is contacted in vitro, in vivo, or ex vivo. In certain embodiments, the c-KIT inhibitor is disclosed herein as compound A or a pharma- ceutically acceptable salt thereof, compound B or a pharma- ceutically acceptable salt thereof, midostaurin or a pharma- ceutically acceptable salt thereof, BLU-285 or a pharma- ceutically acceptable salt thereof, PLX9486 or a pharma- ceutically acceptable salt thereof, or crenolanib or a pharma- ceutically acceptable salt thereof; the MEK inhibitor is disclosed herein as trametinib, cobimetinib, selumetinib, or binimetinib; the ERK inhibitor includes but is not limited to ulixertinib, SCH772984, LY3214996, ravoxertinib, and VX-11e; and the RAF inhibitor includes but is not limited to LY3009120, vemurafenib, or dabrafenib.

[0061] In certain embodiments, the disclosure includes a method of treating a subject having mastocytosis, mast cell leukemia, or acute myeloid leukemia, comprising administering to the subject an effective amount of (i) a KIT inhibitor, e.g., 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea or a pharma- ceutically acceptable salt thereof, or 1-(5-(7-amino-1-ethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-4-bromo-2-fluorophenyl)-3-phenylurea or a pharma- ceutically acceptable salt thereof, and (ii) a MAPKAP pathway inhibitor, e.g., trametinib, binimetinib, or ulixertinib. In certain embodiments of any of the methods disclosed herein, the mastocytosis is systemic mastocytosis resulting from a D816V mutation in the c-KIT gene in mast cells. definition

[0062] As used herein, "Compound A and Compound B" refer to 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea and 1-(5-(7-amino-1-ethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-4-bromo-2-fluorophenyl)-3-phenylurea, respectively. Pharmaceutically acceptable salts, tautomers, hydrates, and solvates of Compound A and Compound B are also contemplated in the present disclosure. The structures of Compound A and Compound B are shown below: [ka] 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea (Compound A) [ka] 1-(5-(7-amino-1-ethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-4-bromo-2-fluorophenyl)-3-phenylurea (Compound B)

[0063] Methods for preparing Compound A and Compound B are disclosed in US Pat. No. 8,461,179 B1, the contents of which are incorporated herein by reference.

[0064] Exemplary methods and materials are described herein. In the specification and the appended claims, the singular form includes the plural form unless otherwise indicated by the context. Unless otherwise specified, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art.

[0065]

[0065] Throughout this disclosure, various patents, patent applications, and publications are referenced. The disclosures of these patents, patent applications, and publications are incorporated by reference in their entireties into this disclosure to more fully describe the state of the art as known to those of skill in the art as of the date of this disclosure. In the event of any inconsistency between these patents, patent applications, and publications and this disclosure, the present disclosure shall control. For convenience, certain terms employed in the present specification, examples and claims are summarized here.Unless otherwise specified, all technical and scientific terms used in this disclosure have the same meaning as commonly understood by those skilled in the art to which this disclosure belongs.The initial definition provided for a group or word provided in this disclosure applies to that group or word individually or as part of another group throughout this disclosure, unless otherwise indicated.

[0066] A "pharmaceutically acceptable carrier, diluent, or excipient" includes, but is not limited to, any adjuvant, carrier, excipient, glidant, sweetener, diluent, preservative, dye / colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, or emulsifier approved by the United States Food and Drug Administration as acceptable for use in humans or veterinary medicine.

[0067] "Pharmaceutically acceptable salts" include acid addition salts.

[0068] "Pharmaceutically acceptable acid addition salts" refers to those salts which retain the biological effectiveness and properties of the free base, which are not biologically or otherwise undesirable, and which are not limited to, inorganic acids such as, for example, but not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like, and also acids such as, but not limited to, acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, camphoric acid, camphor-10-sulfonic acid, capric acid, caproic acid, caprylic acid, carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, formic acid, fumaric acid, acetic ... It is formed from organic acids such as galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid, glucuronic acid, glutamic acid, glutaric acid, 2-oxo-glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, mucic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, 1-hydroxy-2-naphthoic acid, nicotinic acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid, propionic acid, pyroglutamic acid, pyruvic acid, salicylic acid, 4-aminosalicylic acid, sebacic acid, stearic acid, succinic acid, tartaric acid, thiocyanic acid, p-toluenesulfonic acid, trifluoroacetic acid, and undecylenic acid.

[0069] "Pharmaceutical composition" refers to a formulation of a compound described herein (e.g., Compound A or a pharma- ceutically acceptable salt thereof) with a vehicle generally acceptable in the art for the delivery of biologically active compounds to a mammal, e.g., a human. Such vehicles include any pharma- ceutically acceptable carrier, diluent, or excipient therefor.

[0070]

[0001] "MAPKAP pathway inhibitors" are inhibitors of the MAP kinase signaling pathway. Inhibitors of this pathway include RAS inhibitors, RAF inhibitors (e.g., vemurafenib, dabrafenib, LY3009120), MEK inhibitors (e.g., trametinib, binimetinib, cobimetinib), and ERK inhibitors (e.g., ulixertinib).

[0071]

[00070] For example, the present invention is a c-KIT inhibitor in combination with a MAPKAP pathway inhibitor. Subjects or patients "in need of treatment" with the disclosed combination therapy include subjects with diseases and / or conditions that can be treated with the combinations disclosed herein to achieve beneficial therapeutic results, such as mastocytosis, mast cell leukemia, or acute myeloid leukemia. Beneficial outcomes in the treatment of mastocytosis may include complete remission, partial response, clinical improvement, or stable disease as defined by the IWG-MRT-ECNM criteria (Gotlib et al, Blood 2013;121:2393-401). In certain embodiments, the subject in need of treatment is afflicted with cutaneous mastocytosis (e.g., maculopapular cutaneous mastocytosis, mastocytoma, and diffuse cutaneous mastocytosis) or systemic mastocytosis (e.g., indolent systemic mastocytosis, smoldering systemic mastocytosis, systemic mast cells with associated clonal hematologic non-mast cell lineage disease, aggressive systemic mastocytosis, mast cell leukemia, and mast cell sarcoma). In certain embodiments, the subject is a mammal, such as a human or other mammal.

[0072] The term "effective amount," when used in connection with a compound or other therapeutic agent disclosed herein, refers to an amount of a therapeutic agent, e.g., Compound A or a MAPKAP pathway inhibitor, alone or in combination, that is useful for treating or preventing a disease or disorder. An effective amount of a therapeutic agent used is an amount of each therapeutic agent that is useful for treating or preventing a disease or disorder when used in combination therapy, even if the amount of one or both of the therapeutic agents in the absence of the other agent is not effective for treating or preventing the disease or disorder. In certain embodiments, an effective amount is an amount that results in inducing cytocidal mast cell death, inducing apoptosis of mast cells, reducing the amount of accumulated mast cells in a tissue or organ, reducing mastocytosis symptoms, inhibiting mast cell mediator release, inhibiting mast cell proliferation, and / or inducing regression of mast cells, where the mast cells contain an activating mutation in c-KIT kinase, including an activating c-KIT D816V mutation. An "effective amount" can vary depending on the form of administration, the specific location of the disease or disorder, and the age, weight, and general health of the subject. The amount of compound administered will depend on the extent, severity, and type of disease or condition, the amount of treatment desired, and the release characteristics of the pharmaceutical formulation. It will also depend on the subject's health, size, weight, age, sex, and tolerance to the drug. Typically, the compounds are administered for a period of time sufficient to achieve the desired therapeutic effect.

[0073] The terms "treatment", "treat" and "treating" are meant to include the full range of interventions in the patient to be treated, e.g., a patient suffering from mastocytosis or acute myeloid leukemia (AML). Treating may be curing, ameliorating, or at least partially alleviating the disorder. In certain embodiments, treatment is carried out with the intent of inducing cytolethal mast cell death, inducing mast cell apoptosis, reducing the amount of accumulated mast cells in a tissue or organ, reducing mastocytosis symptoms, inhibiting mast cell mediator release, inhibiting mast cell proliferation, and / or inducing mast cell regression in the subject to be treated. In certain embodiments, treatment with the combination therapy disclosed herein alleviates, delays, or reverses one or more of the mastocytosis symptoms and / or induces regression of mastocytosis, even if mastocytosis is not actually eliminated. In some embodiments, treatment includes completely eliminating the disease or disorder, e.g., mastocytosis or AML. In other embodiments, treatment results in a complete response, partial response, clinical improvement, or stable disease as defined by the IWG-MRT-ECNM criteria (Gotlib et al, Blood 2013;121:2393-401).

[0074] As used herein, "mast cells" includes mast cells (also called mast cells) and CD34+ mast cell precursor cells.

[0075] As used herein, "neoplasm" refers to abnormal tissue that grows by more rapid cell proliferation than normal. Neoplasms show a partial or complete lack of structural organization and functional coordination with normal tissue, and usually form a discrete mass of tissue that can be either benign (benign tumor) or malignant (cancer).

[0076]

[00075] As used herein, "tumor" refers to a mass. It may be benign (generally "Tumor" is a term that may refer to either a tumor (harmless in nature) or a malignant (cancerous) growth. Malignant growths may originate in solid organs or bone marrow. The latter are often called liquid tumors. "Tumor" encompasses mast cell leukemia and mast cell sarcoma, collectively referred to herein as "mastocytosis tumors."

[0077] In certain embodiments, the therapeutic effect of treating mastocytosis according to the methods disclosed herein may be measured using standard response criteria known in the art. For example, the "response criteria for complete remission (CR), partial remission (PR), clinical improvement (CI), or stable disease (SD)" used to quantify the effect of treatment on aggressive systemic mastocytosis, mast cell leukemia, and systemic mastocytosis associated with myeloid neoplasms are based on the IWG-M The criteria can be any of those defined by RT-ECNM (Gotlib et al, Blood 2013;121:2393-401). For example, complete remission (CR) requires all four criteria and a response duration of ≥12 weeks with no presence of aggregated compact neoplastic mast cells in the BM or other biopsied organs other than the skin. Serum tryptase levels <20 ng / mL† and peripheral blood count remission defined as ANC with normal differential ≥1×10 9 / L, Hb level ≥ 11 g / dL, and platelet count ≥ 100 × 10 9 / L and complete remission with palpable hepatosplenomegaly and all biopsy-confirmed or suspected SM-related organ damage (CI findings); partial remission (PR)* requires all three criteria and a response duration of ≥12 weeks, with absence of both CR and progressive disease (PD), reduction in neoplastic MC in bone marrow and / or in organs other than skin with biopsy-confirmed SM-related organ damage, reduction in serum tryptase concentration of ≥50%, and resolution of one or more biopsy-confirmed or suspected SM-related organ damage (CI findings); clinical improvement (CI) requires a response duration of ≥12 weeks, one or more of the non-hematopoietic and / or hematopoietic response criteria (see Table 3) to be met, and absence of both CR / PR and progressive disease (PD). Stable disease (SD) is not meeting the criteria for CR, PR, CI, or PD.

[0078] Guidelines for determining response include: (1) only disease-related grade ≥ 2 organ damage is evaluable as a primary endpoint in clinical trials; (2) response determinations of CR, PR, SD, PD, and loss or response (LOR) should apply only to these grade ≥ 2 organ damage findings in the context of the trial; (3) disease status at the time of removing a patient from the trial is specifically related to the updated status of the initial grade ≥ 2 organ damage finding; and (4) exclusion of drug-related toxicity and / or other clinical problems (e.g., gastrointestinal bleeding in cases of worsening anemia or transfusion dependence) must occur before assigning a designated PD or LOR in patients with worsening baseline grade ≥ 2 organ damage.

[0079] In certain embodiments, the therapeutic effect of treating AML according to the methods disclosed herein may be measured using standard response criteria known in the art. For example, the "response criteria for treatment of AML" used to quantify the effect of treatment on AML include minimal residual disease (CR), as defined in Blood. 2017 Jan 26;129(4):424-447. MRD- ), complete remission (CR), CR with incomplete hematologic recovery (CR i ), morphologic leukemia-free state (MLFS), partial response (PR), stable disease (SD), or progressive disease (PD), and are summarized as follows: complete response without minimal residual disease (CR); MRD- ): If pretreatment testing is performed, CR with negative genetic markers by RT-qPCR or CR with negative MFC. Complete remission (CR): bone marrow blasts <5%; no blasts in the bloodstream and no blasts with Auer rods; no extramedullary disease; no extramedullary disease; absolute neutrophil count (ANC) ≥ 1.0 x 10 9 / L (1000 / μL); platelet count ≥ 100 × 10 9 / L (100,000 / μL); CR with incomplete blood recovery (CR i ): Residual neutropenia (<1.0×10 9 / L [1000 / μL]) or thrombocytopenia (<100×10 9 All CR criteria except CR+ (≥ 100,000 / μL [100,000 / μL]); Morphologic Leukemia Free State (MLFS): bone marrow blasts <5%; no blasts with Auer rods; no extramedullary disease; no hematologic recovery required; Partial Response (PR): all hematologic criteria for CR; reduction in bone marrow blast percentage to 5%-25%; and reduction in pretreatment bone marrow blast percentage by at least 50%.

[0080] "Combination therapy" refers to the combination of two or more therapeutic agents, such as a c-KIT inhibitor (Compound A or its derivatives). The treatment includes administering to a patient a therapeutic agent that is a KIT inhibitor, such as a biologically acceptable salt, midostaurin, BLU-285, PLX9486 or crenolanib, and a MAPKAP pathway inhibitor, including but not limited to trametinib, cobimetinib, selumetinib, binimetinib, ulixertinib, LY3009120. Two or more therapeutic agents may be delivered simultaneously, for example in separate pharmaceutical compositions or in the same pharmaceutical composition, or two or more therapeutic agents may be delivered at different times. For example, two or more therapeutic agents may be delivered simultaneously or during overlapping times, and / or one therapeutic agent may be delivered before or after the other therapeutic agent. Treatment involving the combination of a KIT inhibitor, such as compound A, and a MAPKAP pathway inhibitor may include treatment with either single agent preceded or followed by a period of simultaneous treatment with both agents. However, it is intended that during some period of time, an effective amount of two or more therapeutic agents will be present in the patient's body. Treatment method

[0081]

[00080] In one embodiment, the present disclosure relates to a method for treating obesity, e.g., systemic mastocytosis (SM). The disclosure provides a method of treating or preventing mastocytosis, optionally c-KIT-mediated mastocytosis, comprising providing or administering to a subject in need thereof an effective amount of a c-KIT inhibitor in combination with an effective amount of a MAPKAP pathway inhibitor, e.g., trametinib, cobimetinib, selumetinib, binimetinib, ulixertinib, or LY3009120. In one embodiment, the disclosure provides a method of treating or preventing mastocytosis, optionally c-KIT-mediated mastocytosis, e.g., systemic mastocytosis (SM), comprising providing or administering to a subject in need thereof an effective amount of Compound A (or a pharma- ceutically acceptable salt thereof) or Compound B (or a pharma- ceutically acceptable salt thereof) in combination with an effective amount of a MAPKAP pathway inhibitor, e.g., trametinib, cobimetinib, selumetinib, binimetinib, ulixertinib, or LY3009120. In a related embodiment, the disclosure provides a method of treating or preventing mast cell tumors, e.g., mast cell leukemia or mast cell sarcoma, optionally c-KIT mediated mastocytosis, comprising providing or administering to a subject in need thereof an effective amount of a c-KIT inhibitor in combination with an effective amount of a MAPKAP pathway inhibitor, e.g., trametinib, cobimetinib, selumetinib, binimetinib, ulixertinib, or LY3009120. In a related embodiment, the disclosure provides a method of treating or preventing a mast cell tumor, optionally a c-KIT-mediated mast cell tumor, e.g., mast cell leukemia or mast cell sarcoma, comprising providing or administering to a subject in need thereof an effective amount of Compound A (or a pharmaceutically acceptable salt thereof) or Compound B (or a pharmaceutically acceptable salt thereof) in combination with an effective amount of a MAPKAP pathway inhibitor, e.g., trametinib, cobimetinib, selumetinib, binimetinib, ulixertinib, or LY3009120.

[0082] In another embodiment, the disclosure provides a method of treating mastocytosis in a patient in need thereof, comprising administering to the patient an effective amount of a c-KIT inhibitor and an effective amount of one or more MAPKAP pathway inhibitors, which may be selected from the group consisting of rapidly progressing fibrosarcoma (RAF) kinase inhibitors, inhibitors of mitogen-activated protein kinase (MEK inhibitors), and extracellular signal-regulated kinase inhibitors (ERK inhibitors).

[0083] In one embodiment of such disclosed methods, the mastocytosis is associated with a c-KIT mutation. In some embodiments, the c-KIT mutation is an activating mutation.

[0084] In another embodiment, mastocytosis may involve mast cells with a primary mutation in exon 17 of the c-KIT gene. In some embodiments, the primary mutation is a c-KIT D816 mutation. In some embodiments, the primary mutation is one of D816V, D816Y, D816F, D816H, F522C, K5091, V560G, V559G, and del419. In some embodiments, the primary mutation is D816V.

[0085] Mastocytosis may also include mast cells with a c-KIT secondary mutation. In some embodiments, the c-KIT secondary mutation is in one of exons 9, 11, 13, or 17. In some embodiments, the c-KIT secondary mutation is one of the following mutations: Y269C, Y503_F504insAY, V560D, or K642E.

[0086]

[00085] The disclosed method can determine whether mastocytosis is associated with a c-KIT primary mutation. For example, the method further comprises determining whether the mastocytosis is associated with a c-KIT secondary mutation. In some embodiments, determining whether the mastocytosis is associated with a c-KIT primary mutation or determining whether the mastocytosis is associated with a c-KIT secondary mutation comprises identifying a mutation in DNA extracted from the tumor sample. In yet another embodiment, determining whether the mastocytosis is associated with a c-KIT primary mutation or determining whether the mastocytosis is associated with a c-KIT secondary mutation comprises identifying a mutation in tumor DNA in blood or identifying a mutation in peripheral blood leukocytes in blood.

[0087] The mastocytosis may be systemic mastocytosis. In some embodiments, the systemic mastocytosis is selected from the group consisting of inactive systemic mastocytosis, smoldering systemic mastocytosis, systemic mastocytosis with associated clonal hematologic non-mast cell lineage disease, aggressive systemic mastocytosis, mast cell leukemia, and mast cell sarcoma. In some embodiments, the mastocytosis is inactive systemic mastocytosis, optionally with anaphylactic recurrences or systemic mastocytosis with vascular collapse in the absence of skin lesions. In some embodiments, the mastocytosis is smoldering systemic mastocytosis.

[0088] In some embodiments, the mastocytosis is systemic mastocytosis with an associated clonal hematologic non-mast cell lineage disorder. In some embodiments, the mastocytosis is aggressive systemic mastocytosis. In some embodiments, the mastocytosis is mast cell leukemia or mast cell sarcoma. In some embodiments, the mastocytosis is cutaneous mastocytosis. In some embodiments, the mastocytosis is selected from the group consisting of maculopapular cutaneous mastocytosis, mastocytoma, or diffuse cutaneous mastocytosis.

[0089] In such disclosed methods, the c-KIT inhibitor can be selected from the group consisting of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea or a pharma- ceutically acceptable salt thereof, midostaurin or a pharma- ceutically acceptable salt thereof, imatinib mesylate, sunitinab malate, midostaurin, regorafenib, crenolanib, PTX9486, or BLU-285 (avapritinib) or a pharma- ceutically acceptable salt thereof.

[0090] Further, the MEK inhibitor can be selected from the group consisting of trametinib, selumetinib, cobimetinib, and binimetinib. In some embodiments, the MEK inhibitor is binimetinib. In some embodiments, the MEK inhibitor is trametinib. In some embodiments, the ERK inhibitor is selected from the group consisting of ulixertinib, SCH772984, and LY3214996. In some embodiments, the c-KIT inhibitor and the MEK and / or ERK inhibitor are substantially The two agents are administered simultaneously or sequentially.

[0091]

[00090] The method also includes administering to a subject an additional cancer targeted therapeutic agent, a cancer targeted biological agent, or an immune checkpoint inhibitor. This may involve administering an inhibitor, or a chemotherapeutic agent.

[0092] Furthermore, in accordance with the contemplated methods, administration of an effective amount of a c-KIT inhibitor, and administration of an effective amount of an inhibitor of mitogen-activated protein kinase (MEK inhibitor), and / or an effective amount of an extracellular signal-regulated kinase inhibitor (ERK inhibitor) for two or more weeks can result in the patient in at least partial remission.

[0093] Also provided is a method of treating systemic mastocytosis in a patient in need thereof, comprising administering to the patient an effective amount of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea, or a pharma- ceutically acceptable salt thereof, and an effective amount of a MAPKAP pathway inhibitor. In such disclosed methods, the MAPKAP pathway inhibitor is selected from the group consisting of a rapidly progressing fibrosarcoma (RAF) kinase inhibitor, an inhibitor of mitogen-activated protein kinase (MEK inhibitor), and an extracellular signal-regulated kinase inhibitor (ERK inhibitor).

[0094] Systemic mastocytosis, in one embodiment, can be associated with a c-KIT mutation. For example, the mutation can be a c-KIT D816 mutation. In some embodiments, the mutation is one of D816V, D816Y, D816F, D816H, F522C, K5091, V560G, V559G, and del419. In some embodiments, the mutation is one of A553D, C433Y, D419Y, D572A, D816F, D816H, D816I, D816V, D816Y, D820G, del419, dup(501-502), E839K, F522C, I817V, InsFF419, InsV815-I816, K509I, N822I, R815K, T417V, V560G, V559I, or Y418Y. In some embodiments, the mutation is D816V.

[0095] Additionally, mastocytosis may be associated with an additional c-KIT mutation, which is one of the following mutations: Y269C, Y503_F504insAY, V560D, or K642E.

[0096]

[00095] In the disclosed methods, the MEK inhibitor is trametinib, selmetinib, In some embodiments, the MEK inhibitor is binimetinib. In some embodiments, the MEK inhibitor is trametinib. The ERK inhibitor can be selected from the group consisting of ulixertinib, SCH772984, and LY3214996.

[0097] The present disclosure further provides a method of treating mastocytosis in a patient in need thereof, comprising administering to the patient an effective amount of a c-KIT inhibitor and an effective amount of a RAF inhibitor.

[0098] In such disclosed methods, the RAF inhibitor can be a pan-RAF inhibitor or a B-RAF inhibitor, including vemurafenib, dabrafenib, and LY3009120. Additionally, the c-KIT inhibitor can be 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea, or a pharma- ceutically acceptable salt thereof. It is possible.

[0099] Certain embodiments of the methods disclosed herein include methods of treating mastocytosis or mast cell tumors, including inducing cytocidal mast cell death, inducing apoptosis of mast cells, reducing the amount of accumulated mast cells in a tissue or organ, reducing mastocytosis symptoms, inhibiting mast cell mediator release, inhibiting mast cell proliferation, and / or inducing mast cell regression, where the mast cells contain one or more activating mutations in c-KIT kinase, such as, for example, an activating KIT D816V mutation. In certain embodiments, the methods include methods of eradicating mastocytosis, e.g., mast cell tumors, in a subject. In some embodiments, the treatment results in a complete remission, partial response, clinical improvement, or stable disease as defined by IWG-MRT-ECNM criteria (Gotlib et al., Blood 2013;121:2393-401).

[0100] In another related embodiment, the disclosure provides a method of treating or preventing acute myeloid leukemia (AML), optionally c-KIT mediated (AML), comprising administering to a subject in need thereof an effective amount of a c-KIT inhibitor in combination with an effective amount of a MAPKAP pathway inhibitor, e.g., trametinib, cobimetinib, selumetinib, binimetinib, ulixertinib, or LY3009120. In a related embodiment, the disclosure provides a method of treating or preventing acute myeloid leukemia (AML), optionally c-KIT mediated (AML), comprising administering to a subject in need thereof an effective amount of compound A (or a pharma- ceutically acceptable salt thereof) or compound B (or a pharma- ceutically acceptable salt thereof) in combination with an effective amount of a MAPKAP pathway inhibitor, e.g., trametinib, cobimetinib, selumetinib, binimetinib, ulixertinib, or LY3009120.

[0101] [000100] When the methods described herein refer to treatment with compound A or a pharma- ceutically acceptable salt thereof, or with compound B or a pharma- ceutically acceptable salt thereof, it means that only one of compound A or a pharma- ceutically acceptable salt thereof, or compound B or a pharma- ceutically acceptable salt thereof, is required. However, it will be understood that these methods also include administering to a patient both compound A or a pharma- ceutically acceptable salt thereof, and compound B or a pharma- ceutically acceptable salt thereof, in combination with a MAPKAP pathway inhibitor. The methods described herein also include administering compound A and a MAPKAP pathway inhibitor to a subject, whereby compound A is metabolized to compound B in vivo, and the mixture of compound A and compound B in vivo effectively treats the subject in combination with the MAPKAP pathway inhibitor.

[0102] Certain embodiments of the disclosed methods and compositions are practiced using a combination of Compound A, or a pharma- ceutically acceptable salt thereof, and trametinib; a combination of Compound A, or a pharma- ceutically acceptable salt thereof, and selumetinib; a combination of Compound A, or a pharma- ceutically acceptable salt thereof, and cobimetinib; or a combination of Compound A, or a pharma- ceutically acceptable salt thereof, and binimetinib.

[0103] In one embodiment, compound A or a pharma- ceutically acceptable salt thereof and a MEK inhibitor, e.g., trametinib or binimetinib, are administered to a subject suffering from c-KIT-mediated mastocytosis. In another embodiment, compound B or a pharma- ceutically acceptable salt thereof and a MEK inhibitor, e.g., trametinib or binimetinib, are administered to a subject suffering from c-KIT-mediated mastocytosis.

[0104] In a related embodiment, Compound A or a pharma- ceutically acceptable salt thereof may be combined with, for example, In another embodiment, compound B or a pharmaceutically acceptable salt thereof and a MEK inhibitor, such as trametinib or binimetinib, are administered to a patient suffering from a mast cell tumor, including but not limited to mast cell leukemia or mast cell sarcoma, where the growth or progression of the mast cell tumor is caused by an activating c-KIT mutation, such as a KIT D816V mutation. In another embodiment, compound B or a pharmaceutically acceptable salt thereof and a MEK inhibitor, such as trametinib or binimetinib, are administered to a patient suffering from a mast cell tumor, including but not limited to mast cell leukemia or mast cell sarcoma, where the growth or progression of the mast cell tumor is caused by an activating c-KIT mutation, such as a KIT D816V mutation. In certain embodiments, compound A or a pharma- ceutically acceptable salt thereof or compound B or a pharma-ceutically acceptable salt thereof and a MEK inhibitor, for example trametinib or binimetinib, are administered to a patient suffering from AML, optionally wherein the AML is caused by an activating c-KIT primary mutation, for example a c-KIT exon 8 activating mutation or a c-KIT exon 17 mutation, including but not limited to a mutation at D816 or a mutation at N822 (Journal of Clinical Oncology 2006 24:24,3904-3911).

[0105] Certain embodiments of the disclosed methods and compositions are practiced using a combination of Compound A, or a pharma- ceutically acceptable salt thereof, and ulixertinib; a combination of Compound A, or a pharma-ceutically acceptable salt thereof, and SCH772984,e; a combination of Compound A, or a pharma-ceutically acceptable salt thereof, and LY3214996; a combination of Compound A, or a pharma-ceutically acceptable salt thereof, and lavoxertinib; or a combination of Compound A, or a pharma-ceutically acceptable salt thereof, and VX-11.

[0106] [000105] In one embodiment, Compound A or a pharma- ceutically acceptable salt thereof and an ERK inhibitor, e.g., ulixertinib, are administered to a subject suffering from c-KIT-mediated mastocytosis. In another embodiment, Compound B or a pharma- ceutically acceptable salt thereof and an ERK inhibitor, e.g., ulixertinib, are administered to a subject suffering from c-KIT-mediated mastocytosis.

[0107] In a related embodiment, compound A or a pharmaceutically acceptable salt thereof and an ERK inhibitor, e.g., ulixertinib, are administered to a patient suffering from a mast cell tumor, including but not limited to mast cell leukemia or mast cell sarcoma, where the growth or progression of the mast cell tumor is driven by a primary activating c-KIT mutation, e.g., the KIT D816V mutation. In another embodiment, compound B or a pharmaceutically acceptable salt thereof and an ERK inhibitor, e.g., ulixertinib, are administered to a patient suffering from a mast cell tumor, including but not limited to mast cell leukemia or mast cell sarcoma, where the growth or progression of the mast cell tumor is driven by a primary activating c-KIT mutation, e.g., the KIT D816V mutation. In a particular embodiment, compound A or a pharma- ceutically acceptable salt thereof, or compound B or a pharma- ceutically acceptable salt thereof, and an ERK inhibitor, for example ulixertinib, are administered to a patient suffering from AML, optionally caused by a primary activating c-KIT mutation, for example a c-KIT exon 8 activating mutation or a c-KIT exon 17 mutation, including, but not limited to, a mutation at D816 or a mutation at N822 (Journal of Clinical Oncology 2006 24:24,3904-3911).

[0108] Particular embodiments of the disclosed methods and compositions include the combination of Compound A, or a pharma- ceutically acceptable salt thereof, with LY3009120; the combination of Compound A, or a pharma- ceutically acceptable salt thereof, with dabrafenib; or the combination of Compound A, or a pharma- ceutically acceptable salt thereof, with vemurafenib. This is carried out using a combination of.

[0109] In one embodiment, compound A or a pharmaceutically acceptable salt thereof and a RAF inhibitor, e.g., LY3009120, dabrafenib, or vemurafenib, are administered to a subject suffering from c-KIT-mediated mastocytosis. In another embodiment, compound B or a pharmaceutically acceptable salt thereof and a RAF inhibitor, e.g., LY3009120, dabrafenib, or vemurafenib, are administered to a subject suffering from c-KIT-mediated mastocytosis. In a related embodiment, compound A or a pharmaceutically acceptable salt thereof and a RAF inhibitor, e.g., LY3009120, dabrafenib, or vemurafenib, are administered to a patient suffering from a mast cell tumor, including but not limited to mast cell leukemia or mast cell sarcoma, where the growth or tumor progression of the mast cell tumor is caused by a primary activating c-KIT mutation, e.g., KIT D816V mutation. In another embodiment, compound B or a pharmaceutically acceptable salt thereof and a RAF inhibitor, e.g., LY3009120, dabrafenib, or vemurafenib, are administered to a patient suffering from a mast cell tumor, including but not limited to mast cell leukemia or mast cell sarcoma, where the growth or tumor progression of the mast cell tumor is caused by a primary activating c-KIT mutation, e.g., KIT D816V mutation. In certain embodiments, compound A or its pharmaceutically acceptable salt, or compound B or its pharmaceutically acceptable salt, and a RAF inhibitor, for example LY3009120, dabrafenib or vemurafenib, are administered to a patient suffering from AML, optionally wherein the AML is caused by a primary activating c-KIT mutation, for example a c-KIT exon 8 activating mutation or a c-KIT exon 17 mutation, including but not limited to a mutation at D816 or a mutation at N822 (Journal of Clinical Oncology 2006 24:24,3904-3911).

[0110] Exemplary c-KIT inhibitors that can be used according to the disclosed methods and compositions include, but are not limited to, Compound A or a pharmaceutically acceptable salt thereof, Compound B or a pharmaceutically acceptable salt thereof, midostaurin, BLU-285, PLX9486, and crenolanib. Exemplary MEK inhibitors that can be used according to the disclosed methods and compositions include, but are not limited to, trametinib, selumetinib, cobimetinib, and binimetinib. Exemplary ERK inhibitors that can be used according to the disclosed methods and compositions include, but are not limited to, ulixertinib, SCH772984, LY3214996, ravoxertinib, and VX-11e. Exemplary RAF inhibitors that can be used according to the disclosed methods and compositions include, but are not limited to, LY3009120, dabrafenib, and vemurafenib.

[0111] [000110] Treatment with Compound A or a pharma- ceutically acceptable salt thereof, or Compound B or a pharma- ceutically acceptable salt thereof in combination with a MAPKAP pathway inhibitor, e.g., trametinib, binimetinib, ulixertinib, or LY3009120, includes administering Compound A or a pharma- ceutically acceptable salt thereof, or Compound B or a pharma- ceutically acceptable salt thereof, before, after, simultaneously with, or during a period of overlap with administration of the MAPKAP pathway inhibitor. It is understood that the effective amount of any of compound A or a pharma- ceutically acceptable salt thereof, compound B or a pharma- ceutically acceptable salt thereof, another c-KIT inhibitor, or a MAPKAP pathway inhibitor, e.g., trametinib, binimetinib, ulixertinib, or LY3009120, may vary when used in the combinations disclosed herein compared to using any of these agents by themselves for the same purpose, e.g., to treat or prevent mastocytosis or mast cell tumors, e.g., mast cell leukemia or AML. In certain embodiments, In certain embodiments, the effective amount of compound A or a pharma- ceutically acceptable salt thereof, or compound B or a pharma- ceutically acceptable salt thereof, is less when administered in combination with a MAPKAP pathway inhibitor, e.g., trametinib, binimetinib, ulixertinib, or LY3009120, as compared to when administered as a monotherapy, e.g., to treat or prevent mastocytosis or mast cell tumors. In certain embodiments, the effective amount of a MAPKAP pathway inhibitor, e.g., trametinib, binimetinib, ulixertinib, or LY3009120, is less when administered in combination with compound A or a pharma- ceutically acceptable salt thereof, or when administered in combination with compound B or a pharma- ceutically acceptable salt thereof, for treating or preventing mastocytosis or mast cell tumors.

[0112] Any of the methods disclosed herein may further comprise determining whether the mastocytosis cells, mast cell tumor, or AML to be treated is associated with one or more c-KIT gene mutations. Such a determination may be made by conventional methods for determining the presence of gene mutations in a biological sample obtained from a subject, e.g., a bone marrow sample, a tissue sample, a peripheral blood sample, or a plasma sample. Furthermore, such a determination may be made by reviewing the results of tests performed to determine the presence of one or more c-KIT gene mutations in a biological sample obtained from a patient. In certain embodiments of any of the methods disclosed herein, the methods are performed on a subject whose mastocytosis, mast cell tumor, or AML has been identified as associated with one or more c-KIT gene mutations. The c-KIT gene mutations include, but are not limited to, any of those specifically described herein. In certain embodiments of any of the methods disclosed herein, the methods are not performed on a subject whose mastocytosis, mast cell tumor, or AML has been identified as not associated with one or more c-KIT gene mutations.

[0113] In various embodiments of any of the methods disclosed herein, treatment with either Compound A or a pharma- ceutically acceptable salt thereof or Compound B or a pharma- ceutically acceptable salt thereof in combination with a MAPKAP pathway inhibitor, e.g., trametinib, binimetinib, ulixertinib, or LY3009120, induces cytolethal mast cell death, induces apoptosis of mast cells, reduces the amount of accumulated mast cells in a tissue or organ, reduces mastocytosis symptoms, inhibits mast cell mediator release, inhibits mast cell proliferation, and / or induces regression of mast cells, wherein the mast cells express an activated KIT Activating mutations in c-KIT kinase, including the D816V mutation, are included. Methods of measuring or determining the amount of mast cell apoptosis, mast cell death, inhibition of mast cell proliferation and growth, inhibition of mast cell mediator release, mutant KIT allele burden in peripheral blood, eradication of mastocytosis and mast cell tumors, complete remission, partial response, clinical improvement, or stable disease are known in the art and include any of the methods described herein.

[0114] In certain embodiments, treatment with a c-KIT inhibitor, e.g., Compound A or a pharma- ceutically acceptable salt thereof or Compound B or a pharma- ceutically acceptable salt thereof, in combination with a MAPKAP pathway inhibitor, e.g., trametinib, binimetinib, ulixertinib, or LY3009120, results in an increase in the amount of apoptosis of mastocytosis cells or mast cells compared to the amount of apoptosis of the same type of mastocytosis cells or mast cells untreated or treated with the MAPKAP pathway inhibitor alone or with a c-KIT inhibitor alone, e.g., Compound A or Compound B. For example, apoptosis can be increased by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 10-fold, or The increase may be at least 20-fold. In certain embodiments, the amount of apoptosis is determined by measuring caspase activity in KIT mutant mast cells or mast cell lines, including the HMC1.2 mast cell line that contains the KIT D816V mutation.

[0115] In certain embodiments, treatment with a c-KIT inhibitor, e.g., Compound A or a pharma- ceutically acceptable salt thereof, or Compound B or a pharma- ceutically acceptable salt thereof, in combination with a MAPKAP pathway inhibitor, e.g., trametinib, binimetinib, ulixertinib, or LY3009120, results in a decrease in the accumulation of mast cells in the skin or in internal organs, e.g., the liver, spleen, bone marrow, and / or small intestine, compared to the amount of mast cell accumulation in the same organs untreated or treated with only a MAPKAP pathway inhibitor, e.g., trametinib, binimetinib, ulixertinib, or LY3009120, or only a c-KIT inhibitor, e.g., midostaurin, BLU-285, Compound A, or Compound B. For example, the amount or number of mast cells accumulated in an organ can be reduced by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%.

[0116] [000115] In certain embodiments, treatment with a c-KIT inhibitor, e.g., Compound A or a pharma- ceutically acceptable salt thereof, or Compound B or a pharma-ceutically acceptable salt thereof, in combination with a MAPKAP pathway inhibitor, e.g., trametinib, binimetinib, ulixertinib, or LY3009120, results in a complete remission as defined by the IWG-MRT-ECNM criteria (Gotlib et al., Blood 2013;121:2393-401).

[0117] In certain embodiments, treatment with a c-KIT inhibitor, e.g., Compound A or a pharma- ceutically acceptable salt thereof, or Compound B or a pharma-ceutically acceptable salt thereof, in combination with a MAPKAP pathway inhibitor, e.g., trametinib, binimetinib, ulixertinib, or LY3009120, results in a partial response as defined by the IWG-MRT-ECNM criteria (Gotlib et al., Blood 2013;121:2393-401).

[0118] In certain embodiments, treatment with a c-KIT inhibitor, e.g., Compound A or a pharma- ceutically acceptable salt thereof, or Compound B or a pharma-ceutically acceptable salt thereof, in combination with a MAPKAP pathway inhibitor, e.g., trametinib, binimetinib, ulixertinib, or LY3009120, results in clinical improvement as defined by the IWG-MRT-ECNM criteria (Gotlib et al., Blood 2013;121:2393-401).

[0119] In certain embodiments, treatment with a c-KIT inhibitor, e.g., Compound A or a pharma- ceutically acceptable salt thereof, or Compound B or a pharma- ceutically acceptable salt thereof, in combination with a MAPKAP pathway inhibitor, e.g., trametinib, binimetinib, ulixertinib, or LY3009120, results in stable disease as defined by the IWG-MRT-ECNM criteria (Gotlib et al., Blood 2013;121:2393-401).

[0120] In certain embodiments, treatment with a c-KIT inhibitor, e.g., Compound A or a pharma- ceutically acceptable salt thereof, or Compound B or a pharma- ceutically acceptable salt thereof, in combination with a MAPKAP pathway inhibitor, e.g., trametinib, binimetinib, ulixertinib, or LY3009120, induces apoptosis or inhibits proliferation of resistant mastocytosis cells that contain a KIT secondary mutation in addition to the KIT D816V primary mutation. and KIT secondary mutations include, but are not limited to, point mutations, in-frame deletions or insertions, or missense mutations of Y269C, Y503_F504insAY, V560D, or K642E in the c-KIT gene (Lasho et al, Br J Haematol 173, 153-156).

[0121] [000120] In certain embodiments, treatment with a c-KIT inhibitor, e.g., Compound A or a pharma- ceutically acceptable salt thereof, or Compound B or a pharma- ceutically acceptable salt thereof, in combination with a MAPKAP pathway inhibitor, e.g., trametinib, binimetinib, ulixertinib, or LY3009120, induces apoptosis or inhibits proliferation of resistant mastocytosis cells that contain mutations, e.g., resistance mutations, in other genes, including any of the genes disclosed herein. In certain embodiments, such mutations in other genes may include NRas gain of function mutations (Haematologica 2011;96(03):459-463.doi:10.3324 / haematol.2010.031690) or TET2 loss of function mutations (Leukemia 2009;23:900-04;Blood,6 December 2012;120(24):4846-49). The presence of other epigenetic or transcriptional regulator mutations was detected in SM with DNMT3A, ASXL1 and CBL mutations in 12%, 12% and 4% of patients, respectively (PloS 1.2012;7:e43090). Furthermore, some mastocytosis patients also exhibit mutations in the spliceosome machinery. The spliceosome ensures the correct linear order of exons spliced ​​in the mRNA. Hanssens et al. reported a 23.6% incidence of SRSF2, 5.6% SF3B1 and 2.7% U2AF1 mutations in a group of 72 mastocytosis patients (Haematologica 2014;99:830-35). Such mastocytosis with complex genomic drivers may benefit from the treatment disclosed herein with a combination of a c-KIT inhibitor and a MEK inhibitor compared to treatment with only a MEK inhibitor, e.g., trametinib, or with only a c-KIT inhibitor, e.g., Compound A or Compound B, or no treatment.For example, apoptosis can be increased by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 10-fold, or at least 20-fold. For example, the amount or number of proliferation of resistant mastocytosis cells can be inhibited by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%.

[0122] In certain embodiments, the resistant mastocytosis cells are resistant to apoptosis-mediated cell death or cell-destructive activity by treatment with a c-KIT inhibitor, e.g., Compound A, Compound B, midostaurin, BLU-285, PLX9486, or crenolanib, and / or are resistant to apoptosis-mediated cell death or cell-destructive activity by treatment with a MAPKAP pathway inhibitor, e.g., trametinib, binimetinib, ulixertinib, or LY3009120, when used as a monotherapy.

[0123] In certain embodiments, treatment with a combination of a c-KIT inhibitor, e.g., either Compound A or a pharma- ceutically acceptable salt thereof, or Compound B or a pharma-ceutically acceptable salt thereof, in combination with a MAPKAP pathway inhibitor, e.g., trametinib, binimetinib, ulixertinib, or LY3009120, results in eradication of mastocytosis, e.g., mast cell tumors. In certain embodiments, eradication of mastocytosis means that there is no longer any detectable mastocytosis in the patient. In certain embodiments, the eradication of mastocytosis is continued for at least 12 weeks, at least 24 weeks, at least 1 year, at least 2 years, or for at least 2 years after initiation of treatment of mastocytosis with the combination therapy disclosed herein. is the absence of detectable mastocytosis in the patient for at least 5 years. Eradication of mastocytosis can be judged by the criteria of complete remission as defined by the IWG-MRT-ECNM criteria (Gotlib et al, Blood 2013;121:2393-401).

[0124] The present disclosure describes combination therapy involving administration of a c-KIT inhibitor, e.g., either Compound A or a pharma- ceutically acceptable salt thereof, or Compound B or a pharma- ceutically acceptable salt thereof, with a MAPKAP pathway inhibitor, e.g., trametinib, binimetinib, ulixertinib, or LY3009120. The combination therapy described herein can be used by itself or in combination with one or more additional therapeutic agents. For example, either Compound A or a pharma- ceutically acceptable salt thereof, or Compound B or a pharma- ceutically acceptable salt thereof, and a MAPKAP pathway inhibitor can be administered with a cancer targeting therapeutic agent, a cancer targeting biological agent, an immune checkpoint inhibitor, or a chemotherapeutic agent. In another embodiment, Compound A or Compound B and a MAPKAP pathway inhibitor, e.g., trametinib, binimetinib, ulixertinib, or LY3009120, are administered without other therapeutic agents. The therapeutic agent can be administered together with another therapeutic agent described herein in the combination therapy or sequentially with the therapeutic agent.

[0125] Combination therapy can be achieved by administering two or more therapeutic agents, each of which is formulated and administered separately, or by administering two or more therapeutic agents in a single formulation. Other combinations are also encompassed in combination therapy. In combination therapy, two or more therapeutic agents can be administered simultaneously, but not necessarily. For example, administration of a first agent (or combination of agents) can precede administration of a second agent (or combination of agents) by minutes, hours, days, or weeks. Thus, two or more agents can be administered within minutes of each other, or within 1, 2, 3, 6, 9, 12, 15, 18, or 24 hours of each other, or within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14 days of each other, or within 2, 3, 4, 5, 6, 7, 8, 9 weeks or more of each other. In some cases, even longer intervals are possible. In many cases, it is desirable, but not necessary, that the two or more agents used in combination therapy be present in the patient's body at the same time.

[0126] [000125] Combination therapy can also include more than one administration of one or more of the drugs used in the combination, with the component drugs in a different order. For example, when drug X and drug Y are used in combination, they can be administered one or more times sequentially in any combination, e.g., in the order XYX, XXY, YXY, Y--YX, XXYY, etc. Additionally, administration of two or more agents in a combination may be preceded or followed by a dosing interval during which at least one of the agents in the combination is omitted from treatment.

[0127] Additional therapeutic agents that may be administered in accordance with the present disclosure, for example for treating mastocytosis or mast cell tumors, include inhibitors of STAT5, including but not limited to ruxolitinib, tofacitinib, or fedratinib; inhibitors of BTK, including but not limited to ibrutinib, PCI29732, acalabrutinib, or AVL-292; idelalisib, dactolisib, pictilisib, LY294002, buparlisib, pilalalisib, duvelisib, PF-04691502, voxtalisib, omitali Inhibitors of PI3 kinase, including but not limited to parisib, gedatolisib, apitolisib, or wortmannin; inhibitors of AKT kinase, including but not limited to MK-2206, perifosine, GSK690693, GSK2141795, ipatasertib, AZD5363, afuresertib, or AT7867; DNA methylation inhibitors, including but not limited to 5-azacytidine or 5-aza-2'-deoxycytidine; bortezomib, carfilzomib, MLN9708, ONX 0912, interferon alpha (IFN-α), proteosome inhibitors, including but not limited to, cladribine, and lysosomotropic agents, including but not limited to, chloroquine, hydroxychloroquine, or quinacrine.

[0128] In certain embodiments, the additional therapeutic agent is selected from 5-azacytidine, 5-aza-2'-deoxycytidine, and cladribine.

[0129] In certain embodiments, the subject in need thereof is treated with a combination of one or two of compound A or a pharma- ceutically acceptable salt thereof, such as trametinib, binimetinib, ulixertinib, or LY3009120, and a MAPKAP pathway inhibitor that is 5-azacytidine. In certain embodiments, the MAPKAP pathway inhibitor is trametinib. In certain embodiments, the MAPKAP pathway inhibitor is binimetinib. In certain embodiments, the MAPKAP pathway inhibitor is ulixertinib. In certain embodiments, the MAPKAP pathway inhibitor is LY3009120, dabrafenib, or vemurafenib.

[0130] In certain embodiments, the subject in need thereof is treated with a combination of compound A or a pharma- ceutically acceptable salt thereof, such as trametinib, binimetinib, ulixertinib, or LY3009120, and a MAPKAP pathway inhibitor that is 5-aza-2'-deoxycytidine. In certain embodiments, the MAPKAP pathway inhibitor is trametinib. In certain embodiments, the MAPKAP pathway inhibitor is binimetinib. In certain embodiments, the MAPKAP pathway inhibitor is ulixertinib. In certain embodiments, the MAPKAP pathway inhibitor is LY3009120, dabrafenib, or vemurafenib.

[0131] [000130] In certain embodiments, the subject in need thereof is treated with a combination of compound A or a pharma- ceutically acceptable salt thereof, such as trametinib, binimetinib, ulixertinib, or LY3009120, and a MAPKAP pathway inhibitor that is cladribine. In certain embodiments, the MAPKAP pathway inhibitor is trametinib. In certain embodiments, the MAPKAP pathway inhibitor is binimetinib. In certain embodiments, the MAPKAP pathway inhibitor is ulixertinib. In certain embodiments, the MAPKAP pathway inhibitor is LY3009120, dabrafenib, or vemurafenib. Additional therapeutic agents that may be administered according to the present disclosure include, but are not limited to, arsenic trioxide, cyclophosphamide, cytarabine, daunorubicin, doxorubicin, enasidenib, idarubicin, quizartinib, mitoxantrone, thioguanine, or vincristine. In certain embodiments, a subject with AML is treated with a combination of Compound A, or a pharma- ceutically acceptable salt thereof, and arsenic trioxide, cyclophosphamide, cytarabine, daunorubicin, doxorubicin, enasidenib, idarubicin, quizartinib, mitoxantrone, thioguanine, or vincristine.

[0132] Pharmaceutical Compositions Aspects of the present disclosure are directed to methods of treatment that include the administration of combinations of compounds disclosed herein, or one or more pharmaceutical compositions that include such compounds and a pharma- ceutically acceptable diluent, excipient, or carrier.In certain embodiments, the methods disclosed herein involve administering a first pharmaceutical composition that includes a c-KIT inhibitor, e.g., Compound A or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable diluent, excipient, or carrier, and a second pharmaceutical composition that includes a MAPKAP pathway inhibitor, e.g., trametinib, binimetinib, ulixertinib, or LY3009120, and a pharma- cetically acceptable diluent, excipient, or carrier.In certain embodiments, the methods disclosed herein include: The method involves administering a first pharmaceutical composition comprising compound B or a pharma- ceutically acceptable salt thereof and a pharma- ceutically acceptable diluent, excipient or carrier, and a second pharmaceutical composition comprising a MAPKAP pathway inhibitor, e.g., trametinib, binimetinib, ulixertinib, or LY3009120, and a pharma- ceutically acceptable diluent, excipient or carrier. In certain embodiments, the methods disclosed herein involve administering a pharmaceutical composition comprising a ciKIT inhibitor, e.g., compound A or a pharma- ceutically acceptable salt thereof, a MAPKAP pathway inhibitor, e.g., trametinib, binimetinib, ulixertinib, or LY3009120, and a pharma- ceutically acceptable diluent, excipient or carrier. In certain embodiments, the methods disclosed herein involve administering a pharmaceutical composition comprising compound B, or a pharma- ceutical acceptable salt thereof, a MAPKAP pathway inhibitor, e.g., trametinib, binimetinib, ulixertinib, or LY3009120, and a pharma- ceutical acceptable diluent, excipient, or carrier.

[0133] In the use of pharmaceutical compositions of the compounds described herein, pharma- ceutically acceptable carriers can be either solid or liquid. Solid forms include powders, tablets, dispersible granules, capsules, cachets, and suppositories. Powders and tablets may be composed of about 5 to about 95 percent active ingredient. Suitable solid carriers are known in the art, for example, magnesium carbonate, magnesium stearate, talc, sugar, or lactose. Tablets, powders, cachets, and capsules can be used as solid dosage forms suitable for oral administration. Examples of pharma- ceutically acceptable carriers and examples of methods for manufacturing various compositions can be found in A. Gennaro (ed.), Remington's Pharmaceutical Sciences, 18th Edition, (1990), Mack Publishing Co., Easton, Pa., which is incorporated herein by reference in its entirety.

[0134] Liquid form preparations include solutions, suspensions and emulsions.For example, water or water-propylene glycol solutions for parenteral injection, or the addition of sweeteners and opacifiers for oral solutions, suspensions and emulsions.Liquid form preparations also include solutions for intranasal administration.

[0135] In particular, injectable, liquid compositions can be prepared, for example, by dissolving, dispersing, etc. For example, the disclosed compounds are dissolved or mixed in a pharma- ceutically acceptable solvent, such as, for example, water, saline, aqueous dextrose, glycerin, ethanol, etc., to form an injectable isotonic solution or suspension. Proteins, such as albumin, chylomicron particles, or serum proteins, can be used to solubilize the disclosed compounds.

[0136] [000135] Parenteral injectable administration is generally used for subcutaneous, intramuscular, or intravenous injections and infusions. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, or solid forms suitable for dissolving in liquid prior to injection.

[0137] Aerosol preparations suitable for inhalation may also be used. These preparations may include solutions and solids in powder form, which may be in combination with a pharma- ceutically acceptable carrier, such as an inert compressed gas, for example nitrogen.

[0138] Also contemplated for use are solid form preparations which are intended to be converted immediately prior to use into liquid form preparations for either oral or parenteral administration. Such liquid forms include solutions, suspensions, and emulsions.

[0139] dose In some embodiments, when compound A or compound B (or a pharma- ceutically acceptable salt thereof) is used in combination with a MAPKAP pathway inhibitor, e.g., trametinib, binimetinib, ulixertinib, or LY3009120, for a treatment protocol, the two therapeutic agents may be administered together, or in a "dual regimen," the two therapeutic agents may be administered in a dual regimen, where the two therapeutic agents are dosed and administered separately. When compound A or B (or a pharma- ceutically acceptable salt thereof) and a MAPKAP pathway inhibitor are dosed separately, a typical dose of compound A or compound B (or a pharma- ceutically acceptable salt thereof) administered to a subject in need of treatment is typically about 5 mg / day to about 5000 mg / day, and in other embodiments, about 50 mg / day to about 1000 mg / day. Other doses may be from about 10 mmol up to about 250 mmol / day, about 20 mmol to about 70 mmol / day, or about 30 mmol to about 60 mmol / day. The effective dosage of the disclosed compounds, when used with respect to the indicated effects, ranges from about 0.5 mg to about 5000 mg of the disclosed compounds required to treat the condition. Compositions for in vivo or in vitro use can contain about 0.5, 5, 20, 50, 75, 100, 150, 250, 500, 750, 1000, 1250, 2500, 3500, or 5000 mg of the disclosed compounds, or can contain a range of amounts from one to another listed in the dosage list. For oral administration, a typical recommended daily dosage regimen can range from about 1 mg / day to about 500 mg / day, or 1 mg / day to 200 mg / day, in a single dose or in 2 to 4 divided doses. In one embodiment, a typical daily oral dosage regimen is 150 mg.

[0140] In certain embodiments, the dose of the MAPKAP pathway inhibitor is consistent with the doses disclosed above and / or approved for use by the Food and Drug Administration. In other embodiments, the dose of the MAPKAP pathway inhibitor is less than the previously approved dose, e.g., about 20%, about 50%, or about 80% of the approved dose. In certain embodiments, the dose of trametinib is about .5 mg to 20 mg orally per day, e.g., about 1 mg per day, or about 2 mg per day. In certain embodiments, the dose of cobimetinib is about 10 mg to 200 mg per day, e.g., about 30 mg per day, or about 60 mg per day. In certain embodiments, the dose of binimetinib is about 10 mg to 200 mg twice per day, e.g., about 25 mg or about 45 mg twice per day. In certain embodiments, the dose of selumetinib is about 10 mg to 200 mg per day, for example about 30 mg or about 75 mg twice per day.

[0141] [000140] The amount and frequency of administration of the compounds described herein and / or their pharma- ceutically acceptable salts and other therapeutic agents will be adjusted according to the judgment of the attending physician, taking into account factors such as the age, condition and size of the patient, and the severity of the condition being treated.

[0142] The compounds of the present disclosure (e.g., Compound A or Compound B (and its pharma- ceutically acceptable salts), MAPKAP pathway inhibitors, and other therapeutic agents) can be administered by any suitable route. The compounds can be administered orally (e.g., with food) in capsules, suspensions, tablets, pills, dragees, liquids, gels, syrups, slurries, and the like. Methods for encapsulating compositions (such as in hard gelatin or cyclodextran coatings) are known in the art (Baker, et al., “Controlled Release of Biological Active Agents”, John Wiley and Sons, 1986, incorporated herein by reference in its entirety). The compounds can be administered to a subject in conjunction with an acceptable pharmaceutical carrier as part of a pharmaceutical composition. The dosage form of the pharmaceutical composition will vary according to the route of administration selected. A suitable pharmaceutical carrier can include inactive ingredients that do not interact with the compounds. The carrier is biocompatible, i.e., non-toxic, non-inflammatory, non-immunogenic, and does not produce other undesirable reactions at the site of administration.

[0143] Exemplary pharmaceutical compositions include a compound as described herein, e.g., Compound A, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable carrier, e.g., a) a diluent, e.g., purified water, triglyceride oil, e.g., hydrogenated or partially hydrogenated vegetable oil or mixtures thereof, corn oil, olive oil, sunflower oil, safflower oil, fish oil or esters thereof, e.g., EPA or DHA, or triglycerides or mixtures thereof, omega-3 fatty acids or derivatives thereof, lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, sodium, saccharin, glucose, and / or glycine; b) a diluent, e.g., silica, talc, stearic acid, magnesium or calcium salts thereof, sodium oleate, sodium stearate, magnesium stearate, benzoic acid ...stearate, stea c) lubricants, e.g. magnesium aluminium silicate, starch paste, gelatine, tragacanth, methylcellulose, sodium carboxymethylcellulose, magnesium carbonate, natural sugars, e.g. glucose or beta-lactose, corn sweeteners, natural and synthetic gums, e.g. acacia, tragacanth or sodium alginate, waxes and / or polyvinylpyrrolidone, if desired; d) disintegrants, e.g. starch, agar, methylcellulose, bentonite, xanthan gum, alginic acid or its sodium salt, or effervescent mixtures; e) absorbents, colouring agents, flavouring agents and sweetening agents; f) binders, e.g. Tween 80, Labrasol, HPMC, DOSS, Caproyl and / or g) an emulsifier or dispersing agent, such as, for example, cyclodextrin, hydroxypropyl cyclodextrin, PEG 400, PEG 200, or the like, which is an agent that enhances absorption of the compound.

[0144] If prepared as a fixed dose, such combinations will employ the compounds described herein within the dosage ranges described herein or known to those of skill in the art.

[0145] Since the compounds described herein (e.g., Compound A and Compound B and MAPKAP pathway inhibitors) are intended for use in pharmaceutical compositions, those skilled in the art will understand that they can be provided in substantially pure form, for example, at least 60% pure, at least 75% pure, at least 85% pure, and at least 98% pure (w / w). Pharmaceutical preparations may be in unit dosage form. In such preparations, they are prepared by dividing them into appropriately sized unit doses containing an appropriate amount of Compound A or Compound B, e.g., an effective amount to achieve the desired purpose as described herein. EXAMPLES

[0146] [000145] It has been found that the combination treatment of either Compound A or its pharmacologic acceptable salts in combination with a MAPKAP pathway inhibitor unexpectedly and synergistically induces the apoptosis of mast cells driven by mutant c-KIT, which is responsible for systemic mastocytosis. Moreover, this combination treatment inhibits the proliferation of mastocytosis cells. Furthermore, the combination treatment disclosed herein appears to have a cytotoxic effect on mastocytosis, as opposed to being merely cytostatic as determined by the combination treatment induced in caspase activation. The identification of this unexpected discovery was carried out in biochemical and cellular assays, including the assays described herein.

[0147] The present disclosure is further illustrated by the following examples, which are not to be construed as limiting the disclosure in scope or spirit to the specific procedures described herein. It is to be understood that the examples are presented to illustrate certain embodiments and are not intended to limit the scope of the present disclosure. It is further to be understood that various other embodiments, modifications and equivalents may be made that may be suggested to those skilled in the art without departing from the spirit of the present disclosure and / or the scope of the appended claims.

[0148] Example 1. Treatment of mutant KIT mast cell lines with Compound A or Compound B inhibits cell proliferation and KIT phosphorylation in mastocytosis cell lines A study was carried out to demonstrate that treatment with compound A or compound B inhibits cell proliferation of mutant KIT HMC1.1 KIT V560G and HMC1.2 KIT V560G / D816V mast cell lines. The assay was carried out in 96-well plates seeded with 10,000 cells per well. Cells were treated with vehicle control, compound A, or compound B at various concentrations, grown for 72 hours, and then cell proliferation was evaluated.

[0149] Figure 1A is a graphical representation showing the relative percentage of cell proliferation determined for various concentrations of Compound A. Treatment with Compound A inhibited cell proliferation in HMC1.1 V560G and HMC1.2 V560G / D816V mast cell lines with IC50 values ​​of 2.6 nM and 97 nM, respectively.

[0150] Figure 1B is a graphical representation showing the relative percentage of cell proliferation determined for various concentrations of Compound B. Treatment with Compound B inhibited cell proliferation in HMC1.1 V560G and HMC1.2 V560G / D816V mast cell lines with IC50 values ​​of 2.3 nM and 61 nM, respectively.

[0151] Example 2. Combined treatment with Compound A and trametinib induces apoptosis in mastocytosis cell lines [000150] Combination treatment with compound A and the MEK inhibitor trametinib improves HMC1.2 Tests were performed to demonstrate the induction of apoptosis in the KIT V560G / D816V mastocytosis cell line. Assays were performed in 96-well plates seeded with 10,000 cells per well. Cells were treated with vehicle control, Compound A, trametinib, or combinations at various concentrations and allowed to grow for 24 hours. Apoptosis was assessed by measuring caspase 3 / 7 activity.

[0152] Figure 2A is a graphical representation showing the relative percentage of cell apoptosis determined for various treatments. Figure 2B is a matrix diagram of synergy based on the combination index (CI) method described by Chou and Talalay (1984) and Chou and Martin computer software (2005). CI<1 indicates synergy, CI=1 indicates additive effect, and CI>1 indicates antagonism. Unexpectedly, the combination treatment with compound A and MEK inhibitor trametinib showed strong synergy to induce apoptosis of HMC1.2 KIT V560G / D816V cells. Figure 2C is a combination index plot of CI, demonstrating the strong synergy of the combination of compound A and trametinib to induce apoptosis of HMC1.2 KIT V560G / D816V mast cells.

[0153] Example 3. Combined treatment with Compound B and trametinib induces apoptosis in mastocytosis cell lines Tests were also performed to demonstrate that combined treatment with Compound B and trametinib induces apoptosis in the HMC1.2 KIT V560G / D816V mastocytosis cell line. The assay was performed as described in Example 2. Apoptosis was assessed by measuring caspase 3 / 7 activity.

[0154] Figure 3A is a graphical representation showing the relative percentage of cell apoptosis determined for various treatments. Figure 3B is a matrix diagram of synergy based on the combination index (CI) method described by Chou and Talalay (1984) and Chou and Martin computer software (2005). CI<1 indicates synergy, CI=1 indicates additive effect, and CI>1 indicates antagonism. Unexpectedly, the combination treatment with compound B and MEK inhibitor trametinib showed strong synergy to induce apoptosis of HMC1.2 KIT V560G / D816V cells. Figure 3C is a combination index plot of CI, demonstrating the strong synergy of the combination of compound B and trametinib to induce apoptosis of HMC1.2 KIT V560G / D816V mast cells.

[0155] Example 4. Combined treatment with Compound A and binimetinib induces apoptosis in mastocytosis cell lines Combined treatment with Compound A and binimetinib also induces apoptosis in the HMC1.2 KIT V560G / D816V mastocytosis cell line. Assays were performed as described in Example 2. Apoptosis was assessed by measuring caspase 3 / 7 activity.

[0156] [000155] Figure 4A is a graph showing the relative percentage of cell apoptosis determined for various treatments. Figure 4B is a matrix diagram of synergy based on the combination index (CI) method described by Chou and Talalay (1984) and Chou and Martin computer software (2005). Unexpectedly, the combination treatment with compound A and MEK inhibitor binimetinib showed strong synergy to induce apoptosis of HMC1.2 KIT V560G / D816V cells. Figure 4C is a combination index plot of CI, demonstrating the strong synergy of the combination of compound A and binimetinib to induce apoptosis of HMC1.2 KIT V560G / D816V mast cells.

[0157] Example 5. Combined treatment with Compound B and binimetinib induces apoptosis in mastocytosis cell lines Figure 5A is a graphical representation showing the relative percentage of cell apoptosis determined for various treatments of compound B and binimetinib. Figure 5B is a matrix diagram of synergy based on the combination index (CI) method described by Chou and Talalay (1984) and computer software of Chou and Martin (2005). CI<1 indicates synergy, CI=1 indicates additive effect, and CI>1 indicates antagonism. Unexpectedly, the combination treatment with compound B and MEK inhibitor binimetinib showed strong synergy to induce apoptosis of HMC1.2 KIT V560G / D816V cells. Figure 5C is a combination index plot of CI, demonstrating the strong synergy of the combination of compound B and binimetinib to induce apoptosis of HMC1.2 KIT V560G / D816V mast cells.

[0158] Example 6. Combined treatment with Compound A and cobimetinib induces apoptosis in mastocytosis cell lines Figure 6A is a graphical representation showing the relative percentage of cell apoptosis determined for various treatments of Compound A and Cobimetinib. Figure 6B is a matrix diagram of synergy based on the Combination Index (CI) method described by Chou and Talalay (1984) and Chou and Martin's computer software (2005). Unexpectedly, combination therapy with Compound A and the MEK inhibitor Cobimetinib showed strong synergy in inducing apoptosis in HMC1.2 KIT V560G / D816V cells. Figure 6C is a combination index plot of CI, showing the synergy of HMC1.2 KIT V560G / D816V cells. We demonstrate potent synergy for the combination of Compound A and cobimetinib to induce apoptosis of 16V mast cells.

[0159] Example 7. Combined treatment with Compound B and cobimetinib induces apoptosis in mastocytosis cell lines Figure 7A is a graphical representation showing the relative percentage of cell apoptosis determined for various treatments of compound B and cobimetinib. Figure 7B is a matrix diagram of synergy based on the combination index (CI) method described by Chou and Talalay (1984) and computer software of Chou and Martin (2005). CI<1 indicates synergy, CI=1 indicates additive effect, and CI>1 indicates antagonism. Unexpectedly, the combination treatment with compound B and MEK inhibitor cobimetinib showed strong synergy for inducing apoptosis of HMC1.2 KIT V560G / D816V cells. Figure 7C is a combination index plot of CI, demonstrating the strong synergy of the combination of compound B and cobimetinib to induce apoptosis of HMC1.2 KIT V560G / D816V mast cells.

[0160] Example 8. Combined treatment with Compound A and ulixertinib induces apoptosis in mastocytosis cell lines Figure 8A is a graphical representation showing the relative percentage of cell apoptosis determined for various treatments of compound A and ERK inhibitor ulixertinib. Figure 8B is a matrix diagram of synergy based on the combination index (CI) method described by Chou and Talalay (1984) and computer software of Chou and Martin (2005). Unexpectedly, the combination treatment with compound A and ulixertinib showed strong synergy to induce apoptosis of HMC1.2 KIT V560G / D816V cells. Figure 8C is a combination index plot of CI, demonstrating the strong synergy of the combination of compound A and ulixertinib to induce apoptosis of HMC1.2 KIT V560G / D816V mast cells.

[0161] Example 9. Combined treatment with Compound B and ulixertinib induces apoptosis in mastocytosis cell lines [000160] The combination treatment of compound B and ERK inhibitor ulixertinib can be evaluated for inducing apoptosis in HMC1.2 KIT V560G / D816V mast cells. A matrix diagram of synergy based on combination index (CI) method can be generated as described by Chou and Talalay (1984) and Chou and Martin computer software (2005). The combination treatment of compound B and ulixertinib can be used to show the synergy of inducing apoptosis in HMC1.2 KIT V560G / D816V cells. The combination index plot of CI can be used to demonstrate the strong synergy of the combination of compound B and ulixertinib in inducing apoptosis in HMC1.2 KIT V560G / D816V mast cells.

[0162] Example 10. Combined treatment with Compound A and SCH772984 induces apoptosis in mastocytosis cell lines Combination treatment of Compound A and ERK inhibitor SCH772984 can be evaluated for inducing apoptosis in HMC1.2 KIT V560G / D816V mast cells. A matrix diagram of synergy based on the combination index (CI) method can be generated as described by Chou and Talalay (1984) and computer software of Chou and Martin (2005). Combination treatment with Compound A and SCH772984 can be used to show synergy in inducing apoptosis in HMC1.2 KIT V560G / D816V cells. CI combination index plot can be used to demonstrate synergy for the combination of Compound A and SCH772984 in inducing apoptosis in HMC1.2 KIT V560G / D816V mast cells.

[0163] Example 11. Combined treatment with Compound B and SCH772984 induces apoptosis in mastocytosis cell lines The combination treatment of compound B and ERK inhibitor SCH772984 can be evaluated for inducing apoptosis in HMC1.2 KIT V560G / D816V mast cells. A matrix diagram of synergy based on combination index (CI) method can be generated as described by Chou and Talalay (1984) and Chou and Martin computer software (2005). The combination treatment of compound A and SCH772984 can be used to show the synergy of inducing apoptosis of HMC1.2 KIT V560G / D816V cells. The combination index plot of CI can be used to demonstrate the synergy of the combination of compound B and SCH772984 inducing apoptosis of HMC1.2 KIT V560G / D816V mast cells.

[0164] Example 12. Combined treatment with Compound A and LY3009120 induces apoptosis in mastocytosis cell lines The combination treatment of compound A and RAF inhibitor LY3009120 can be evaluated for inducing apoptosis in HMC1.2 KIT V560G / D816V mast cells. A matrix diagram of synergy based on combination index (CI) method can be generated as described by Chou and Talalay (1984) and Chou and Martin computer software (2005). The combination treatment of compound A and LY3009120 can be used to show the synergy of inducing apoptosis of HMC1.2 KIT V560G / D816V cells. The combination index plot of CI can be used to demonstrate the strong synergy of the combination of compound A and LY3009120 in inducing apoptosis of HMC1.2 KIT V560G / D816V mast cells.

[0165] Example 13. Combined treatment with Compound B and LY3009120 induces apoptosis in mastocytosis cell lines The combination treatment of compound B and RAF inhibitor LY3009120 can be evaluated for inducing apoptosis in HMC1.2 KIT V560G / D816V mast cells. A matrix diagram of synergy based on combination index (CI) method can be generated as described by Chou and Talalay (1984) and Chou and Martin computer software (2005). The combination treatment of compound B and LY3009120 can be used to show the synergy of inducing apoptosis in HMC1.2 KIT V560G / D816V cells. The combination index plot of CI can be used to show the synergy of the combination of compound B and LY3009120 inducing apoptosis in HMC1.2 KIT V560G / D816V mast cells.

[0166] Example 14. Combined treatment with Compound A and trametinib leads to a synergistic decrease in colony growth of the HMC1.2 KIT D816V mast cell line [000165] A study was conducted to demonstrate that combined treatment with Compound A and the MEK inhibitor trametinib leads to a decrease in colony growth of HMC1.2 compared to treatment with either single agent. 10,000 HMC1.2 cells were grown in soft agar and incubated for 10 days with various concentrations of Compound A, trametinib, or a combination of Compound A and trametinib. Drug treatment was removed and colony growth of viable cells was observed after an additional 5 days. Figure 9A shows representative photographs of colony growth of HMC1.2 mast cells following treatment with trametinib (0, 10, or 25 nM), compound A (0, 25, or 50 nM), either as single agents or as a matrix of various concentrations of compound A combined with various concentrations of trametinib. Single agent treatment with compound A or trametinib resulted in colony growth at all concentrations 5 days after drug removal, while the combination of compound A and trametinib resulted in little colony growth 5 days after drug removal. The combination of compound A (25 nM) with trametinib (25 nM) completely eradicated colony growth 5 days after drug removal. Combination of compound A (50 nM) with trametinib (10 or 25 nM) unexpectedly resulted in complete eradication of viable HMC1.2 cell proliferation to the limit of detection as determined by visualization by stereomicroscopy at 5x 5 days after drug removal, whereas treatment with single agent compound A or single agent trametinib did not observe eradication. Further extension of colony proliferation to an additional 8 days after drug removal (total of 13 days) maintained eradication to the limit of detection of colony proliferation with combination of compound A (50 nM) and trametinib (10 and 25 nM). However, incubation with combination of compound A (25 nM) and trametinib (25 nM) resulted in the proliferation of approximately 15-20 colonies after an additional 8 days (Figure 9A right panel).

[0167] Figure 9B is a graphical representation quantifying colony growth of HMC1.2 mast cells after various treatments from Figure 9A. Combination treatment with 50 nM compound A and either 10 nM or 25 nM trametinib unexpectedly resulted in eradication of colony growth to the limit of detection as determined by visualization by stereomicroscopy at 5x (Figure 9B, see arrow). Combination treatment with 25 nM compound A and 25 nM trametinib unexpectedly resulted in eradication of colony growth to the limit of detection as determined by visualization by stereomicroscopy at 5x (Figure 9B, see arrow), eradication not observed with treatment with either single agent compound A or trametinib.

[0168] Example 15. Combined treatment with compound B and trametinib leads to a synergistic decrease in colony growth of the HMC1.2 KIT D816V mast cell line Studies were also performed with Compound B and the MEK inhibitor trametinib to assess the reduction of colony growth in HMC1.2 cells as described in Example 14.

[0169] Figure 10A shows representative photographs of colony growth of HMC1.2 mast cells after treatment with trametinib (0, 10, or 25 nM), compound B (0, 25, or 50 nM) as single agents or as a matrix of various concentrations of compound B combined with various concentrations of trametinib. Single agent treatment with compound B or trametinib resulted in colony growth at all concentrations 5 days after drug removal, while the combination of compound B and trametinib resulted in little colony growth 5 days after drug removal. The combination of compound B (25 nM) with trametinib (25 nM) significantly reduced the growth of live HMC1.2 cells 5 days after drug removal. Combination of compound B (50 nM) with trametinib (10 or 25 nM) unexpectedly resulted in complete eradication of viable HMC1.2 cell proliferation to the limit of detection as determined by visualization by stereomicroscopy at 5x 5 days after drug removal, while no eradication was observed with treatment with single agent compound B or single agent trametinib. With colony growth further extended to an additional 8 days after drug removal (total of 13 days), eradication remained maintained to the limit of detection of colony growth with the combination of compound B (50 nM) and trametinib (25 nM). FIG 10B is a graphical representation quantifying colony growth of HMC1.2 mast cells after various treatments from FIG 10A. Combination treatment with 50 nM Compound B and either 10 nM or 25 nM trametinib unexpectedly resulted in eradication of colony growth to the limit of detection as determined by visualization by stereomicroscopy at 5x, whereas eradication was not observed with treatment with either single agent Compound B or trametinib (FIG 10B, arrows). (see markings).

[0170] Example 16. Combined treatment with Compound A and binimetinib leads to a synergistic decrease in colony growth of the HMC1.2 KIT D816V mast cell line FIG. 11A shows representative photographs of colony growth of HMC1.2 mast cells after treatment with binimetinib (0, 250, or 500 nM), compound A (0, 25, or 50 nM), either as single agents or as a matrix of various concentrations of compound A combined with various concentrations of binimetinib. Single agent treatment with compound A or binimetinib resulted in colony growth at all concentrations 5 days after drug removal, while the combination of compound A and binimetinib resulted in little colony growth 5 days after drug removal. The combination of compound A (25 nM) with binimetinib (250 nM) significantly reduced the growth of live HMC1.2 cells 5 days after drug removal. The combination of Compound A (50 nM) with binimetinib (250 nM or 500 nM) unexpectedly resulted in complete eradication of viable HMC1.2 cell proliferation to the limit of detection as determined by visualization by stereomicroscopy at 5x 5 days after drug removal, while no eradication was observed with treatment with single agent Compound A or single agent binimetinib. With colony proliferation further extended to an additional 8 days after drug removal (total of 13 days), the combination of Compound A (50 nM) and binimetinib (500 nM) maintained eradication to the limit of detection of colony proliferation. However, the combination of Compound A (50 nM) and binimetinib (250 nM) allowed the proliferation of approximately 10-15 colonies.

[0171] [000170] Figure 11B is a graphical representation quantifying colony growth of HMC1.2 mast cells after various treatments from Figure 11A. Combination treatment with 50 nM Compound A and 250 nM or 500 nM binimetinib unexpectedly resulted in eradication of colony growth to the limit of detection as determined by visualization by stereomicroscopy at 5x; eradication was not observed with treatment with either single agent Compound A or binimetinib (Figure 11B, see arrows).

[0172] Example 17. Combined treatment with compound B and binimetinib leads to a synergistic decrease in colony growth of the HMC1.2 KIT D816V mast cell line Figure 12A shows representative photographs of colony growth of HMC1.2 mast cells after treatment with binimetinib (0, 250, or 500 nM), compound B (0, 25, or 50 nM) as single agents or as a matrix of various concentrations of compound B combined with various concentrations of binimetinib. Single agent treatment with compound B or binimetinib resulted in colony growth at all concentrations 5 days after drug removal, while the combination of compound B and binimetinib resulted in little colony growth 5 days after drug removal. The combination of compound B (25 nM) with binimetinib (250 nM) significantly reduced the growth of live HMC1.2 cells 5 days after drug removal. Combination of Compound B (25 nM) with binimetinib (500 nM) resulted in complete eradication of viable HMC1.2 cell proliferation to the limit of detection as determined by visualization by stereomicroscopy at 5x magnification 5 days after drug removal. Combination of Compound B (50 nM) with binimetinib (250 nM or 500 nM) unexpectedly resulted in complete eradication of viable HMC1.2 cell proliferation to the limit of detection as determined by visualization by stereomicroscopy at 5x magnification 5 days after drug removal, whereas no eradication was observed with treatment with single agent Compound B or single agent binimetinib. With colony growth further extended to an additional 8 days (total 13 days) after drug removal, eradication remained maintained down to the limit of detection of colony growth with the combination of Compound B (50 nM) with binimetinib (250 or 500 nM) and Compound B (25 nM) with binimetinib (500 nM).

[0173] Figure 12B is a graphical representation quantifying colony growth of HMC1.2 mast cells after various treatments from Figure 12A. Combination treatment with 25 nM Compound B and 500 nM binimetinib and combination treatment with 50 nM Compound B and either 250 nM or 500 nM binimetinib. Combination treatment with Compound B unexpectedly resulted in eradication of colony growth to the limit of detection as determined by visualization by stereomicroscopy at 5x magnification, whereas eradication was not observed with treatment with either single agent Compound B or binimetinib (Figure 12B, see arrows).

[0174] Example 18. Combined treatment with Compound A and cobimetinib leads to a synergistic decrease in colony growth of the HMC1.2 KIT D816V mast cell line Figure 13A shows representative photographs of colony growth of HMC1.2 mast cells after treatment with cobimetinib (0, 25, or 50 nM), compound A (0, 25, or 50 nM), either as single agents or as a matrix of various concentrations of compound A combined with various concentrations of cobimetinib. Single agent treatment with compound A or cobimetinib resulted in colony growth at all concentrations 5 days after drug removal, while the combination of compound A and cobimetinib resulted in little colony growth 5 days after drug removal compared to either single agent treatment. The combination of compound A (50 nM) with cobimetinib (25 or 50 nM) significantly reduced the growth of live HMC1.2 cells 5 days after drug removal.

[0175] Figure 13B is a graphical representation quantifying colony growth of HMC1.2 mast cells after various treatments from Figure 13A. Combination treatment with 50 nM Compound A and either 25 nM or 50 nM cobimetinib resulted in a significant decrease in colony growth compared to either Compound A or cobimetinib alone.

[0176] Example 19. Combined treatment with Compound B and cobimetinib leads to a synergistic decrease in colony growth of the HMC1.2 KIT D816V mast cell line [000175] Figure 14A shows representative photographs of colony growth of HMC1.2 mast cells after treatment with cobimetinib (0, 25, or 50 nM), compound B (0, 25, or 50 nM), either as single agents or as a matrix of various concentrations of compound B combined with various concentrations of cobimetinib. Single agent treatment with compound B or cobimetinib resulted in colony growth at all concentrations 5 days after drug removal, while the combination of compound B and cobimetinib resulted in little colony growth 5 days after drug removal compared to either single agent treatment. The combination of compound B (50 nM) with cobimetinib (25 or 50 nM) significantly reduced the growth of live HMC1.2 cells 5 days after drug removal.

[0177] Figure 14B is a graphical representation quantifying colony growth of HMC1.2 mast cells after various treatments from Figure 14A. Combination treatment with 50 nM Compound B and either 25 nM or 50 nM cobimetinib resulted in a significant decrease in colony growth compared to either Compound B or cobimetinib alone.

[0178] Example 20. Combined treatment with Compound A and the ERK inhibitor ulixertinib leads to a synergistic decrease in colony growth of the HMC1.2 KIT D816V mast cell line Combination treatment with Compound A and ulixertinib can be evaluated for inhibition of colony growth of the HMC1.2 KIT D816V mast cell line according to the method of Example 14.

[0179] Example 21. Combined treatment with Compound B and the ERK inhibitor ulixertinib leads to a synergistic decrease in colony growth of the HMC1.2 KIT D816V mast cell line Combination treatment of Compound B and ulixertinib can be evaluated for inhibition of colony growth of the HMC1.2 KIT D816V mast cell line according to the method of Example 14.

[0180] Example 22. Combined treatment with compound A and the RAF inhibitor LY3009120 leads to a synergistic decrease in colony growth of the HMC1.2 KIT D816V mast cell line Combined treatment with Compound A and the RAF inhibitor LY3009120 can be evaluated for inhibition of colony growth of the HMC1.2 KIT D816V mast cell line according to the method of Example 14.

[0181] Example 23. Combined treatment with compound B and LY3009120 leads to a synergistic decrease in colony growth of the HMC1.2 KIT D816V mast cell line [000180] Combined treatment of Compound B and the RAF inhibitor LY3009120 can be evaluated for inhibition of colony growth of the HMC1.2 KIT D816V mast cell line according to the method of Example 14.

[0182] Example 24. Combined treatment with Compound A and the MEK inhibitor trametinib induces apoptosis in the mutant N-ras G12D-transfected HMC1.2 KIT V560G / D816V mastocytosis cell line A study was performed to demonstrate that combined treatment with Compound A and Trametinib induces apoptosis in mutant N-ras G12D transfected HMC1.2 V560G / D816V cells. The assay was performed in 96-well plates seeded with 10,000 cells per well. Cells were treated with vehicle control, Compound A, Trametinib, or their combination at various concentrations, and the cells were grown for 24 and 48 hours. Apoptosis was assessed by measuring caspase 3 / 7 activity.

[0183] Figure 15A is a graphical representation showing the relative percentage of caspase activity determined for various treatments at 24 hours.Combined treatment with Compound A and Trametinib for 24 hours induces apoptosis in HMC1.2 V560G / D816V cells transfected with empty vector (EV) (left panel) or mutant N-ras G12D (right panel).Combination of Compound A with Trametinib leads to a synergistic increase in apoptosis in HMC1.2 cells transfected with EV and HMC1.2 cells transfected with N-ras G12D.

[0184] Figure 15B is a graphical representation showing the relative percentage of caspase activity determined for various treatments at 48 hours. Combination treatment with Compound A and Trametinib for 48 hours induced apoptosis in HMC1.2 V560G / D816V cells transfected with empty vector (EV) (left panel) or mutant N-ras G12D (right panel). Combination of Compound A with Trametinib led to a synergistic increase in apoptosis in HMC1.2 cells transfected with EV and HMC1.2 cells transfected with N-ras G12D. There was more apoptosis in N-ras transfected cells than in EV transfected cells.

[0185] Example 25. Combined treatment with Compound A and the MEK inhibitor cobimetinib induces apoptosis in the mutant N-ras G12D-transfected HMC1.2 KIT V560G / D816V mastocytosis cell line Figure 16A is a graphical representation showing the relative percentage of caspase activity determined for various treatments at 24 hours. Combination treatment with Compound A and Cobimetinib for 24 hours induced apoptosis in HMC1.2 V560G / D816V cells transfected with empty vector (EV) (left panel) or mutant N-ras G12D (right panel). Combination of Compound A with Cobimetinib led to a synergistic increase in apoptosis in HMC1.2 cells transfected with EV and HMC1.2 cells transfected with N-ras G12D. There was more apoptosis in N-ras transfected cells than in EV transfected cells.

[0186] [000185] Figure 16B shows caspase activity determined for various treatments at 48 hours. 1 is a graphical representation showing the relative percentage of. Combination treatment with compound A and cobimetinib for 48 hours induced apoptosis in HMC1.2 V560G / D816V cells transfected with empty vector (EV) (left panel) or mutant N-ras G12D (right panel). Combination of compound A with cobimetinib led to a synergistic increase in apoptosis in EV-transfected and N-ras G12D-transfected HMC1.2 cells. There was more apoptosis in N-ras-transfected cells than in EV-transfected cells.

[0187] Example 26. Combination treatment with compound A and the MEK inhibitor trametinib inhibits N-ras Transfection with G12D or empty vector leads to a synergistic decrease in colony growth of the HMC1.2 KIT D816V mast cell line A study was performed to demonstrate that combined treatment with Compound A and trametinib leads to a decrease in colony growth of HMC1.2 cells transfected with empty vector (EV) or N-ras G12D compared to treatment with either agent alone. HMC1.2 cells were incubated with various concentrations of Compound A, trametinib, or a combination of Compound A and trametinib for 10 days. Drug treatment was removed and colony growth of viable cells was observed after an additional 5 or 13 days.

[0188] Figure 17A shows representative photographs of colony growth of EV-transfected HMC1.2 mast cells following treatment with trametinib (0, 1, 10, or 25 nM), compound A (0, 25, or 50 nM), either as single agents or as a matrix combining various concentrations of compound A with various concentrations of trametinib. Single agent treatment with compound A or trametinib resulted in colony growth at all concentrations 5 days after drug removal, while the combination of compound A and trametinib resulted in little colony growth 5 days after drug removal. The combination of compound A (50 nM) with trametinib (1 nM) resulted in a significant decrease in colony growth compared to single agent compound A or single agent trametinib, with 1 nM trametinib. The combination of Compound A (50 nM) with trametinib (10 or 25 nM) unexpectedly resulted in complete eradication of viable HMC1.2 cell proliferation to the limit of detection as determined by visualization by stereomicroscopy at 5x 5 days after drug removal, while no eradication was observed with treatment with single agent Compound A or single agent trametinib. With further extended colony growth for an additional 8 days after drug removal (total of 13 days after drug removal), eradication remained maintained to the limit of detection of colony growth with the combination of Compound A (50 nM) and trametinib (25 nM).

[0189] Figure 17B is a graphical representation quantifying colony growth of HMC1.2 mast cells transfected with EVs after various treatments from Figure 17A. Combination treatment with 50 nM Compound A and either 10 nM or 25 nM Trametinib unexpectedly resulted in eradication of colony growth to the limit of detection as determined by visualization by stereomicroscopy at 5x, whereas eradication was not observed with treatment with either single agent Compound A or Trametinib (Figure 17B, see arrows).

[0190] FIG. 17C shows representative photographs of colony growth of N-ras G12D transfected HMC1.2 cells following treatment with trametinib (0, 1, 10, or 25 nM), compound A (0, 25, or 50 nM), either as single agents or as a matrix combining various concentrations of compound A with various concentrations of trametinib. Single agent treatment with compound A or trametinib resulted in colony growth at all concentrations 5 days after drug removal, while the combination of compound A and trametinib resulted in little colony growth 5 days after drug removal. The combination of compound A (25 nM) with trametinib (25 nM) resulted in a significant decrease in the proliferation of viable HMC1.2 cells 5 days after drug removal, and unexpectedly, the combination of compound A (50 nM) with trametinib (10 or 25 nM) resulted in a 5-fold decrease in the proliferation of viable HMC1.2 cells 5 days after drug removal. Compound A (50 nM) and trametinib (25 nM) combination resulted in complete eradication of proliferation of N-ras G12D-transfected HMC1.2 cells to the limit of detection as determined by visualization by stereomicroscopy at 37 °C, whereas eradication was not observed with treatment with either single agent Compound A or trametinib. Colony growth was further extended for an additional 8 days after drug removal (total of 13 days after drug removal), with the combination of Compound A (50 nM) and trametinib (25 nM) maintaining eradication of colony growth (Figure 17C).

[0191] [000190] Figure 17D is a graphical representation quantifying colony growth of various treatments from Figure 17C. Combination treatment with Compound A and trametinib resulted in superior inhibition of colony growth compared to treatment with either single agent. Unexpectedly, combination treatment with 50 nM Compound A and either 10 nM or 25 nM trametinib resulted in eradication of colony growth to the limit of detection as determined by visualization by stereomicroscopy at 5x 5 days after drug removal, which was not observed with treatment with either single agent Compound A or trametinib (see arrow in Figure 17D).

[0192] Example 27. Combined treatment with Compound A and cobimetinib leads to a synergistic decrease in colony growth of HMC1.2 KIT D816V mast cell lines transfected with N-ras G12D or empty vector A study was performed to demonstrate that combination treatment with Compound A and cobimetinib leads to a decrease in colony growth of HMC1.2 cells transfected with empty vector (EV) or N-ras G12D compared to treatment with either agent alone. HMC1.2 cells were incubated with various concentrations of Compound A, cobimetinib, or the combination of Compound A and cobimetinib for 10 days. Drug treatment was removed and colony growth of viable cells was observed after an additional 5 or 10 days.

[0193] Figure 18A shows representative photographs of colony growth of EV-transfected HMC1.2 mast cells following treatment with cobimetinib (25, or 50 nM), compound A (0, 25, or 50 nM), either as single agents or as a matrix combining various concentrations of compound A with various concentrations of cobimetinib. Single agent treatment with compound A or cobimetinib resulted in colony growth at all concentrations 5 days after drug removal, while the combination of compound A and cobimetinib resulted in little colony growth 5 days after drug treatment was removed. The combination of compound A (25 nM) with cobimetinib (25 and 50 nM) significantly reduced the growth of live HMC1.2 cells 5 days after drug treatment was removed. The combination of Compound A (50 nM) with cobimetinib (50 nM) unexpectedly resulted in complete eradication of viable HMC1.2 cell proliferation to the limit of detection as determined by visualization by stereomicroscopy at 5x magnification 5 days after removal of drug treatment, while no eradication was observed with treatment with single agent Compound A or single agent cobimetinib. With colony proliferation further extended to an additional 5 days after removal of drug treatment (a total of 10 days after drug removal), eradication remained maintained to the limit of detection of colony proliferation with the combination of Compound A (50 nM) and cobimetinib (50 nM).

[0194] Figure 18B is a graphical representation quantifying colony growth of HMC1.2 mast cells transfected with EVs after various treatments from Figure 18A. Combination treatment with 50 nM Compound A and 50 nM cobimetinib unexpectedly resulted in eradication of colony growth to the limit of detection as determined by visualization by stereomicroscopy at 5x, whereas eradication was not observed with treatment with either single agent Compound A or cobimetinib (Figure 18B, see arrows).

[0195] FIG. 18C shows the progression of N-ras G12D transfected HCC cells following treatment with cobimetinib (0, 25, or 50 nM), Compound A (0, 25, or 50 nM), either as single agents or as a matrix combining various concentrations of Compound A with various concentrations of cobimetinib. Representative photographs of colony growth of MC1.2 mast cells. Single agent treatment with Compound A or Cobimetinib resulted in colony growth at all concentrations 5 days after removal of drug treatment, while the combination of Compound A and Cobimetinib resulted in little colony growth 5 days after removal of drug treatment. Combination of Compound A (25 nM) with Cobimetinib (25 and 50 nM) significantly reduced the proliferation of live HMC1.2 cells 5 days after removal of drug treatment. Combination of Compound A (50 nM) with Cobimetinib (25 or 50 nM) unexpectedly resulted in complete eradication of proliferation of live HMC1.2 cells to the limit of detection as determined by visualization by stereomicroscopy at 5x 5 days after removal of drug treatment, while treatment with single agent Compound A or single agent Cobimetinib did not result in eradication. With colony growth further extended to an additional 10 days after removal of drug treatment, eradication remained maintained to the limit of detection of colony growth with the combination of Compound A (50 nM) and cobimetinib (25 or 50 nM).

[0196] [000195] Figure 18D is a graphical representation quantifying colony growth after various treatments from Figure 18C. Combination treatment with Compound A and cobimetinib resulted in superior inhibition of colony growth compared to treatment with either single agent. Unexpectedly, combination treatment with 50 nM Compound A and 25 nM or 50 nM cobimetinib resulted in eradication of colony growth to the limit of detection as determined by visualization by stereomicroscopy at 5x 5 days after drug removal, whereas eradication was not observed with treatment with either single agent Compound A or cobimetinib (see arrows in Figure 18D).

[0197] Equivalent Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments specifically described in this disclosure which equivalents are intended to be encompassed by the following claims.

Claims

1. 1. A medicament for use in the treatment of mastocytosis in a patient in need thereof, comprising: Compound B: [Formula 1] or a pharma- ceutically acceptable salt thereof; and an effective amount of one or more MAPKAP pathway inhibitors selected from the group consisting of mitogen-activated protein kinase (MEK inhibitors), extracellular signal-regulated kinase inhibitors (ERK inhibitors), and rapidly progressing fibrosarcoma (RAF) kinase inhibitors; A medicine comprising a combination of the above.

2. The pharmaceutical composition of claim 1, wherein the mastocytosis is associated with a c-KIT mutation.

3. The pharmaceutical composition according to claim 1 or 2, wherein the c-KIT mutation is an activating mutation.

4. The method according to any one of claims 1 to 3, wherein the mastocytosis involves mast cells with a primary mutation in exon 17 of the c-KIT gene.

5. The method of claim 4, wherein the primary mutation is a c-KIT D816 mutation.

6. 6. The medicament of claim 4 or 5, wherein the primary mutation is one of D816V, D816Y, D816F, D816H, F522C, K5091, V560G, V559G, and del419.

7. The pharmaceutical of claim 4 or 5, wherein the primary mutation is D816V.

8. The pharmaceutical agent according to any one of claims 1 to 7, wherein the mastocytosis involves mast cells with a c-KIT secondary mutation.

9. The method of claim 8, wherein the c-KIT secondary mutation is in one of exons 9, 11, 13, or 17.

10. The pharmaceutical according to claim 8 or 9, wherein the c-KIT secondary mutation is one of the following mutations: Y269C, Y503_F504insAY, V560D or K642E.

11. The method of any one of claims 5 to 10, wherein the treatment further comprises determining whether the mastocytosis is associated with a c-KIT primary mutation.

12. The method of any one of claims 5 to 10, wherein the treatment further comprises determining whether the mastocytosis is associated with a c-KIT secondary mutation.

13. The method of claim 11 or 12, wherein determining whether the mastocytosis is associated with a c-KIT primary or secondary mutation comprises identifying the mutation in DNA extracted from a tumor sample.

14. The method of claim 11 or 12, wherein determining whether the mastocytosis is associated with a primary c-KIT mutation or a secondary c-KIT mutation comprises identifying a mutation in circulating tumor DNA or in circulating peripheral blood leukocytes.

15. The pharmaceutical composition according to claim 1 , wherein the mastocytosis is systemic mastocytosis.

16. The pharmaceutical composition of claim 15, wherein the systemic mastocytosis is selected from the group consisting of indolent systemic mastocytosis, smoldering systemic mastocytosis, systemic mastocytosis with associated clonal hematologic non-mast cell lineage disease, aggressive systemic mastocytosis, mast cell leukemia, and mast cell sarcoma.

17. The pharmaceutical composition of claim 15, wherein the mastocytosis is indolent systemic mastocytosis, optionally with anaphylactic recurrences or vascular collapse not involving skin lesions.

18. The pharmaceutical composition according to claim 15, wherein the mastocytosis is smoldering systemic mastocytosis.

19. The pharmaceutical composition of claim 15, wherein the mastocytosis is systemic mastocytosis with an associated clonal hematologic non-mast cell lineage disorder.

20. The pharmaceutical composition according to claim 15, wherein the mastocytosis is aggressive systemic mastocytosis.

21. The pharmaceutical composition of claim 15, wherein the mastocytosis is mast cell leukemia or mast cell sarcoma.

22. The pharmaceutical composition according to claim 1 , wherein the mastocytosis is cutaneous mastocytosis.

23. The pharmaceutical composition of claim 22, wherein the mastocytosis is selected from the group consisting of maculopapular cutaneous mastocytosis, mastocytoma, or diffuse cutaneous mastocytosis.

24. The pharmaceutical agent according to any one of claims 1 to 23, wherein the MAPKAP pathway inhibitor is a MEK inhibitor selected from the group consisting of trametinib, selumetinib, cobimetinib, and binimetinib.

25. The pharmaceutical agent of claim 24, wherein the MEK inhibitor is binimetinib.

26. The pharmaceutical agent of claim 24, wherein the MEK inhibitor is trametinib.

27. The pharmaceutical agent according to any one of claims 1 to 23, wherein the MAPKAP pathway inhibitor is an ERK inhibitor selected from the group consisting of ulixertinib, SCH772984, and LY3214996.

28. The pharmaceutical composition according to any one of claims 1 to 27, wherein the c-KIT inhibitor and the MEK inhibitor and / or the ERK inhibitor are adapted to be administered simultaneously or sequentially.

29. 29. The pharmaceutical of any one of claims 1 to 28, wherein the treatment further comprises using another cancer targeted therapeutic agent, cancer targeted biological agent, immune checkpoint inhibitor, or chemotherapeutic agent.

30. 30. The method of claim 1, wherein the patient is in at least partial remission after 2 weeks or more of use of the medicament.

31. 1. A medicament for use in the treatment of systemic mastocytosis in a patient in need thereof, comprising: Compound B: [chemical 2] or a pharma- ceutically acceptable salt thereof; and an effective amount of one or more MAPKAP pathway inhibitors selected from the group consisting of mitogen-activated protein kinase (MEK inhibitors), and extracellular signal-regulated kinase inhibitors (ERK inhibitors); It is a combination of the MEK inhibitor is selected from the group consisting of trametinib, selumetinib, cobimetinib, and binimetinib; The ERK inhibitor is selected from the group consisting of ulixertinib, SCH772984, and LY3214996. Medicine.

32. The pharmaceutical agent according to claim 31 , wherein the systemic mastocytosis is associated with a c-KIT mutation.

33. The pharmaceutical agent of claim 31 , wherein the mutation is a c-KIT D816 mutation.

34. 34. The pharmaceutical of claim 33, wherein the mutation is one of D816V, D816Y, D816F, D816H, F522C, K5091, V560G, V559G, and del419.

35. 35. The medicament of claim 34, wherein the mutation is one of A553D, C433Y, D419Y, D572A, D816F, D816H, D816I, D816V, D816Y, D820G, del419, dup(501-502), E839K, F522C, I817V, InsFF419, InsV815-I816, K509I, N822I, R815K, T417V, V560G, V559I or Y418Y.

36. The pharmaceutical agent of any one of claims 31 to 35, wherein the mutation is D816V.

37. The method of any one of claims 31 to 35, wherein the mastocytosis is associated with an additional c-KIT mutation which is one of the following mutations: Y269C, Y503_F504insAY, V560D, or K642E.

38. The pharmaceutical agent according to any one of claims 31 to 37, wherein the MAPKAP pathway inhibitor is a MEK inhibitor selected from the group consisting of trametinib, selumetinib, cobimetinib, and binimetinib.

39. The pharmaceutical agent of claim 38, wherein the MEK inhibitor is binimetinib.

40. The pharmaceutical agent of claim 38, wherein the MEK inhibitor is trametinib.

41. The pharmaceutical agent according to any one of claims 31 to 37, wherein the MAPKAP pathway inhibitor is an ERK inhibitor selected from the group consisting of ulixertinib, SCH772984, and LY3214996.

42. 1. A medicament for use in the treatment of mastocytosis in a patient in need thereof, comprising: Compound B: [C3] or a pharma- ceutically acceptable salt thereof; and an effective amount of a RAF inhibitor; A medicine comprising a combination of the above.

43. The pharmaceutical composition of claim 42, wherein the RAF inhibitor is a pan-RAF inhibitor.

44. The pharmaceutical agent of claim 42, wherein the RAF inhibitor is selected from the group consisting of LY3009120, vemurafenib, and dabrafenib.